Form 6-K TITAN MEDICAL INC For: Feb 26
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Titan Medical Inc.
(Exact Name of Registrant as Specified in Charter)
155 University Avenue, Suite 750
(Address of principal executive offices)
TITAN MEDICAL INC.
|
||||
(Registrant)
|
||||
|
||||
Date:
|
February 26, 2021
|
By:
|
/s/ Monique L. Delorme
|
|
Name:
|
Monique L. Delorme
|
|||
Title:
|
Chief Financial Officer
|
Issuer:
|
Titan Medical Inc. (the “Company”).
|
Offering:
|
8,335,000 units of the Company (the “Units”) for aggregate
gross proceeds of $20,004,000 (which amount does not include the exercise of the
Over-Allotment Option) (the “Offering”).
|
Issue Price:
|
$2.40 per Unit (the “Issue Price”).
|
Offered Securities:
|
Each Unit consists of one common share of the Company (a “Common
Share”) and one half (1/2) of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable to
acquire one Common Share for a period of 24 months following the closing of the Offering at an exercise price of $3.00 per share.
|
Form of Offering:
|
Bought deal by way of short form prospectus pursuant to NI 44-101 in each of the provinces British Columbia, Alberta, and Ontario (collectively, the “Offering Jurisdictions”), by way of private placement in the United States, or to or for the account or benefit of U.S. Persons, solely pursuant to an
exemption from the registration requirements of the U.S. Securities Act, and applicable state securities laws, and in such other jurisdictions outside of Canada and the United States as are agreed to by the Company and the Underwriters
provided that sales into such jurisdictions will not give rise to any registration or continuous disclosure obligations in such jurisdictions.
|
Over-Allotment Option:
|
The Company has granted the Underwriters an Over-Allotment Option, exercisable at any time and from time to time for a period of 30
days following closing, to purchase at the Issue Price up to such number of additional Units and/or Warrants as is equal to 15% of the number of Units sold pursuant to the Offering.
|
Listing:
|
The Company shall use best efforts to obtain the necessary approvals to list the Common Shares comprising of the Units (including any additional Units),
Common Shares underlying the Warrants (including any additional Warrants) and Common Shares underlying any broker warrants on the Toronto Stock Exchange, which listing shall be conditionally approved prior to the Closing Date subject only to
customary post-closing listing conditions.
|
Standstill:
|
The Company has agreed that for a period of 90 days after the Closing Date, it will not, without the written consent of Bloom
Burton, on behalf of the Underwriters, issue, any shares or any securities convertible into or exchangeable for shares of the Company except (i) in connection with the exchange, conversion or exercise of existing outstanding securities or
existing commitments to issue securities, (ii) in connection with an arm’s length acquisition, or (iii) pursuant to the grant of stock options or other compensation securities exercisable or convertible into shares of the Company pursuant to
any long term incentive plan.
|
Lock-Up:
|
The Company’s executive officers and directors will also agree, prior to Closing, not to sell any common shares or securities
exchangeable or convertible into common shares of the Company for a period of 90 days following the Closing Date without Bloom Burton’s prior written consent, on behalf of the Underwriters, such consent not to be unreasonably withheld.
|
Eligibility:
|
The Common Shares and Warrants comprising the Units (including additional Common Shares and additional Warrants that are issued upon the exercise of the
Over-Allotment Option) will be qualified investments under the Income Tax Act (Canada) for RRSPs, RESPs, RRIFs, RDSPs, DPSPs, and TFSAs.
|
Use of Proceeds:
|
The net proceeds of the Offering will be used to fund the development of the Company’s robotic surgical technologies and general working capital.
|
Commission:
|
7.0% cash fee plus that number of broker warrants equal to 7.0% of the Units sold under the Offering (including Units sold pursuant to the exercise of the
Over-Allotment Option), each entitling the holder to acquire one Common Share at US$3.75 for a period of 24 months after the Closing Date.
|
Closing Date:
|
On or about February 23, 2021 (the “Closing Date”) or such other date as the Lead Underwriter
and the Company may agree.
|
Underwriter:
|
Bloom Burton Securities Inc.
|
Titan Medical Announces Filing of Preliminary Short Form Prospectus
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
TORONTO--(BUSINESS WIRE)--February 8, 2021--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has filed a preliminary short form prospectus with applicable securities regulators in Ontario, British Columbia and Alberta in connection with its previously announced offering of 8,335,000 units of the Company (“Units”) on a “bought deal” basis, at a price of US$2.40 per Unit (the “Offering Price”) for aggregate gross proceeds of US$20,004,000 (the “Offering”). Bloom Burton Securities Inc. (the “Underwriter”) will act as underwriter for the Offering.
Each Unit will consist of one common share in the capital of the Company (each a “Common Share”) and one half (1/2) of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable to acquire one Common Share during the period of 24 months following the closing of the Offering at an exercise price of US$3.00 per share.
The Company has granted the Underwriter an option, exercisable in whole or in part and from time to time at any time until 30 days after the closing of the Offering, to purchase up to an additional number of Units equal to 15% of the number of Units sold pursuant to the Offering at the Offering Price.
The net proceeds of the Offering will be used to fund the development of the Company’s robotic surgical technologies and for general working capital. The Offering is expected to close on or about February 23, 2021 or such other date as the Company and the Underwriter may agree, and is subject to certain closing conditions, including but not limited to, the receipt of all necessary regulatory, stock exchange and other approvals, including the approval of the Toronto Stock Exchange.
The Units will be offered by way of a short form prospectus to be filed in each of the provinces of British Columbia, Alberta, and Ontario pursuant to National Instrument 44-101 – Short Form Prospectus Distributions, and by way of private placement in the United States and to, or for the account or benefit of “U.S. persons” (as defined in Regulation S under the United States Securities Act of 1933, as amended (the “1933 Act”)) pursuant to exemptions from the registration requirements under the 1933 Act, and pursuant to the applicable securities laws of any state of the United States. The Units may also be sold in such other jurisdictions as the Company and the Underwriter may agree.
The securities referred to in this news release have not been, nor will they be, registered under the 1933 Act and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This press release does not constitute an offer for sale of securities, nor a solicitation for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
About Titan Medical
Titan Medical Inc., a medical device company headquartered in Toronto, is focused on developing robotic assisted technologies for application in single access surgery. The Enos™ system, by Titan Medical, is being developed with dual 3D and 2D high-definition vision systems, multi-articulating instruments, and an ergonomic surgeon workstation. With the Enos system, Titan intends to initially pursue gynecologic surgical indications. Certain of Titan’s robotic assisted surgical technologies and related intellectual property have been licensed to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system.
Enos™ is a trademark of Titan Medical Inc.
For more information, visit www.titanmedicalinc.com.
Forward-Looking Statements of Titan Medical
This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws. Such statements reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements, including, without limitation, references to: the Company’s focus on the design and development of surgical technologies for robotic single access surgery, the constituent securities that will make up the Units and the terms of the Warrants, the use of proceeds from the Offering, the aggregate gross proceeds of the Offering and the exercise of the overallotment option, the expected filing of the prospectus, the expected closing date of the Offering, ability to obtain Toronto Stock Exchange approval, the jurisdictions in which the Units will be offered, that the Enos system is being developed with dual 3D and 2D high-definition vision systems, multi-articulating instruments and an ergonomic surgeon workstation and that Titan intends to initially pursue gynecologic surgical indications. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 (which may be viewed at www.sedar.com and at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Contacts
Monique L. Delorme
Chief Financial Officer
+1-416-548-7522
[email protected]
Titan Medical Announces Filing of Final Short Form Prospectus
Not for Distribution to United States News Wire Services or for Dissemination in the United States
TORONTO--(BUSINESS WIRE)--February 19, 2021--Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has filed and been receipted for a final short form prospectus with applicable securities regulators in Ontario, British Columbia and Alberta in connection with its previously announced offering of 8,335,000 units of the Company (“Units”) on a “bought deal” basis, at a price of US$2.40 per Unit (the “Offering Price”) for aggregate gross proceeds of US$20,004,000 (the “Offering”). Bloom Burton Securities Inc. (the “Underwriter”) will act as underwriter for the Offering.
Each Unit will consist of one common share in the capital of the Company (each a “Common Share”) and one half (1/2) of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable to acquire one Common Share for a period of 24 months following the closing of the Offering at an exercise price of US$3.00 per share.
The Company has granted the Underwriter an option, exercisable in whole or in part and from time to time at any time until 30 days after the closing of the Offering, to purchase up to an additional number of Units equal to 15% of the number of Units sold pursuant to the Offering at the Offering Price.
The net proceeds of the Offering will be used to fund the development of the Company’s robotic surgical technologies and for general working capital. The Offering is expected to close on or about February 24, 2021 or such other date as the Company and the Underwriter may agree, and is subject to certain closing conditions, including but not limited to, the receipt of all necessary regulatory, stock exchange and other approvals, including the approval of the Toronto Stock Exchange. The Company received conditional approval from the Toronto Stock Exchange on February 11, 2021.
The Units are being offered by way of a short form prospectus in each of the provinces of British Columbia, Alberta, and Ontario pursuant to National Instrument 44-101 – Short Form Prospectus Distributions, and by way of private placement in the United States and to, or for the account or benefit of “U.S. persons” (as defined in Regulation S under the United States Securities Act of 1933, as amended (the “1933 Act”)) pursuant to exemptions from the registration requirements under the 1933 Act, and pursuant to the applicable securities laws of any state of the United States. The Units may also be sold in such other jurisdictions as the Company and the Underwriter may agree.
The securities referred to in this news release have not been, nor will they be, registered under the 1933 Act and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This press release does not constitute an offer for sale of securities, nor a solicitation for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
About Titan Medical
Titan Medical Inc., a medical device company headquartered in Toronto, is focused on developing robotic assisted technologies for application in single access surgery. The Enos™ system, by Titan Medical, is being developed with dual 3D and 2D high-definition vision systems, multi-articulating instruments, and an ergonomic surgeon workstation. With the Enos system, Titan intends to initially pursue gynecologic surgical indications. Certain of Titan’s robotic assisted surgical technologies and related intellectual property have been licensed to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system.
Enos™ is a trademark of Titan Medical Inc.
For more information, visit www.titanmedicalinc.com.
Forward-Looking Statements of Titan Medical
This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws. Such statements reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements, including, without limitation, references to: the Company’s focus on the design and development of surgical technologies for robotic single access surgery, the constituent securities that will make up the Units and the terms of the Warrants, the use of proceeds from the Offering, the aggregate gross proceeds of the Offering, the expected closing date of the Offering, the jurisdictions in which the Units will be offered, that the Enos system is being developed with dual 3D and 2D high-definition vision systems, multi-articulating instruments and an ergonomic surgeon workstation and that Titan intends to initially pursue gynecologic surgical indications. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 (which may be viewed at www.sedar.com and at www.sec.gov) and in the “Risk Factors” section of the Company’s prospectus as of the date hereof (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Contacts
Monique L. Delorme
Chief Financial Officer
+1-416-548-7522
[email protected]
ARTICLE I INTERPRETATION
|
1
|
|
1.1
|
Definitions
|
1
|
1.2
|
Number and Gender
|
7
|
1.3
|
Interpretation Not Affected by Headings, Etc.
|
7
|
1.4
|
Day Not a Business Day
|
7
|
1.5
|
Governing Law
|
7
|
1.6
|
Currency
|
7
|
1.7
|
Meaning of “Outstanding”
|
7
|
1.8
|
Severability
|
7
|
1.9
|
Statutory References
|
7
|
ARTICLE II ISSUE OF WARRANTS |
8 |
|
2.1 |
Issue of Warrants |
8 |
2.2 |
Form and Terms of Warrants |
8 |
2.3 |
Issue in Substitution for Lost Warrant Certificates |
9 |
2.4 |
Non-Certificated Deposit |
9 |
2.5 |
Warrantholder not a Shareholder |
11 |
2.6 |
Warrants to Rank Pari Passu |
11 |
2.7 |
Signing of Warrant Certificates |
12 |
2.8 |
Certification by the Warrant Agent |
12 |
2.9 |
Legended Warrant Certificates |
12 |
2.10 |
Copy of Indenture |
14 |
ARTICLE III EXCHANGE AND OWNERSHIP OF WARRANTS; NOTICES |
14 |
|
3.1 |
Exchange of Warrant Certificates | 14 |
3.2 |
Registration of Warrants | 15 |
3.3 |
Transfer of Warrants | 16 |
3.4 |
Ownership of Certificates | 17 |
3.5 |
Evidence of Ownership | 17 |
3.6 |
Notices | 18 |
ARTICLE IV EXERCISE OF WARRANTS |
18 |
|
4.1 |
Method of Exercise of Warrants | 18 |
4.2 |
Effect of Exercise of Warrants | 20 |
4.3 |
Subscription for Less than Entitlement | 21 |
4.4 |
No Fractional Common Shares | 21 |
4.5 |
Expiration of Warrant Certificates | 22 |
4.6 |
Cancellation of Surrendered Warrants | 22 |
4.7 |
Accounting and Recording | 22 |
4.8 |
Prohibition on Exercise by U.S. Persons; Exception | 22 |
ARTICLE V ADJUSTMENT OF SUBSCRIPTION RIGHTS AND EXERCISE PRICE |
24 |
|
5.1 |
Adjustment of Exercise Price and Number of Common Shares Purchasable Upon Exercise | 24 |
5.2 |
Rules Regarding Calculation of Adjustment of Exercise Price and Number of Common Shares Purchasable Upon Exercise | 28 |
5.3 |
Postponement of Subscription | 31 |
5.4 |
Notice of Adjustment of Exercise Price and Number of Common Shares Purchasable Upon Exercise |
32 |
ARTICLE VI PURCHASES BY THE COMPANY |
32 |
|
6.1 |
Purchases of Warrants for Cancellation | 32 |
6.2 |
Optional Purchases by the Company | 32 |
ARTICLE VII COVENANTS OF THE COMPANY |
33 |
|
7.1 |
Covenants of the Company | 33 |
7.2 |
Warrant Agent’s Remuneration and Expenses | 34 |
7.3 |
Performance of Covenants by Warrant Agent | 34 |
7.4 |
Securities Filings | 34 |
7.5 |
Certificates of No Default | 35 |
ARTICLE VIII ENFORCEMENT |
35 |
|
8.1 |
Suits by Warrantholders | 35 |
8.2 |
Limitation of Liability | 37 |
ARTICLE IX MEETINGS OF WARRANTHOLDERS |
37 |
|
9.1 |
Right to Convene Meetings | 37 |
9.2 |
Notice | 37 |
9.3 |
Chairman | 37 |
9.4 |
Quorum | 38 |
9.5 |
Power to Adjourn | 38 |
9.6 |
Show of Hands | 38 |
9.7 |
Poll and Voting | 38 |
9.8 |
Regulations | 39 |
9.9 |
Company, Warrant Agent and Warrantholders May be Represented | 39 |
9.10 |
Powers Exercisable by Extraordinary Resolution | 40 |
9.11 |
Meaning of Extraordinary Resolution | 41 |
9.12 |
Powers Cumulative | 41 |
9.13 |
Minutes | 42 |
9.14 |
Instruments in Writing | 42 |
9.15 |
Binding Effect of Resolutions | 42 |
9.16 |
Holdings by Company Disregarded | 42 |
ARTICLE X SUPPLEMENTAL INDENTURES |
43 |
|
10.1 |
Provision for Supplemental Indentures for Certain Purposes | 43 |
10.2 |
Successor Companies | 44 |
ARTICLE XI CONCERNING THE WARRANT AGENT |
44 |
|
11.1 |
Indenture Legislation | 44 |
11.2 |
Rights and Duties of Warrant Agent | 44 |
11.3 |
Evidence, Experts and Advisers | 45 |
11.4 |
Action by Warrant Agent to Protect Interest | 46 |
11.5 |
Warrant Agent not Required to Give Security | 46 |
11.6 |
Protection of Warrant Agent | 46 |
11.7 |
Replacement of Warrant Agent; Successor by Merger | 47 |
11.8 |
Conflict of Interest | 48 |
11.9 |
Warrant Agent Not to be Appointed Receiver | 48 |
11.10 |
Payments by Warrant Agent | 48 |
11.11 | Deposit of Securities | 48 |
11.12 | Act, Error, Omission etc. | 48 |
11.13 | Indemnification | 49 |
11.14 | Notice | 49 |
11.15 | Reliance by the Warrant Agent | 49 |
11.16 | Privacy | 50 |
11.17 | Anti-Money Laundering | 50 |
11.18 | Force Majeure | 50 |
ARTICLE XII ACCEPTANCE OF TRUSTS BY WARRANT AGENT |
51 |
|
12.1 |
Appointment and Acceptance of Functions | 51 |
ARTICLE XIII GENERAL |
51 |
|
13.1 |
Notice to the Company and the Warrant Agent | 51 |
13.2 |
Time of the Essence | 52 |
13.3 |
Counterparts and Formal Date | 52 |
13.4 |
Discretion of Directors | 53 |
13.5 |
Satisfaction and Discharge of Indenture | 53 |
13.6 |
Provisions of Indenture and Warrant Certificates for the Sole Benefit of Parties and Warrantholders | 53 |
13.7 |
Common Shares or Warrants Owned by the Company or its Subsidiaries Certificates to be Provided | 53 |
Schedule “A” Form of Warrant Certificate | 1 |
Schedule “B” Form of Declaration For Removal of U.S. Legend | 1 |
INTERPRETATION
1.1
|
Definitions
|
(a)
|
“Affiliate” has the meaning ascribed thereto in the Securities Act (Ontario), as
amended or replaced from time to time;
|
(b)
|
“Agent” means Bloom Burton Securities Inc.;
|
(c)
|
“Authenticated” means (a) with respect to the issuance of a Warrant Certificate,
one which has been duly signed by the Company and authenticated by manual signature of an authorized officer of the Warrant Agent, (b) with respect to the issuance of an Uncertificated Warrant, one in respect of which the Warrant Agent has
completed all Internal Procedures such that the particulars of such Uncertificated Warrant as required by Section 2.9 are entered in the register of Warrantholders, “Authenticate”, “Authenticating” and “Authentication” have the appropriate
correlative meanings;
|
(d)
|
“Business Day” means a day which is not Saturday or Sunday or a statutory holiday
in the City of Toronto or a day on which the principal office of the Warrant Agent in the City of Toronto is closed;
|
(e)
|
“Beneficial Owner” means a person that has a beneficial interest in the Warrant
that is represented by a Warrant Certificate or Uncertificated Warrant registered in the name of CDS or its nominee, the purposes of being held by or on behalf of CDS as custodians for CDS Participants;
|
(f)
|
“Capital Reorganization” has the meaning attributed thereto in subsection 5.1(d);
|
(g)
|
“CDS” or the “Depository” means CDS
Clearing and Depository Services Inc. or its nominee;
|
(h)
|
“CDS Participant” means a broker, dealer, bank or other financial institution or
other person for whom, from time to time, CDS effects book entries for the Warrants deposited with CDS;
|
(i)
|
“Closing Date” has the meaning ascribed to such term in the Prospectus;
|
(j)
|
“Common Shares” means the common shares in the capital of the Company as such
shares exist at the close of business on the date hereof and, in the event that there shall occur a change in respect of or affecting the Common Shares referred to in Section 5.1 (whether or not such change shall result in an adjustment in
the Exercise Price), the term “Common Shares” shall mean the shares, other securities or other property which a Warrantholder is entitled to purchase upon the exercise of Warrants resulting from such change;
|
(k)
|
“Common Share Reorganization” has the meaning attributed thereto in
subsection 5.1(a);
|
(l)
|
“Company” means Titan Medical Inc., a corporation existing under the laws of the
Province of Ontario, and its lawful successors from time to time;
|
(m)
|
“Company’s Auditors” means the chartered accountant or firm of chartered
accountants duly appointed as auditor or auditors of the Company from time to time;
|
(n)
|
“Confirmation” means a confirmation sent by CDS to the Warrant Agent in connection
with the exercise of a Warrant by a Beneficial Owner through a CDS Participant;
|
(o)
|
“Counsel” means a barrister or solicitor (who may be an employee of the Company)
or a firm of barristers and solicitors (who may be counsel to the Company), in both cases acceptable to the Warrant Agent, acting reasonably;
|
(p)
|
“Court” has the meaning attributed thereto in subsection 11.7(1);
|
(q)
|
“Current Market Price” at any date, means the volume weighted average price per
share at which the Common Shares have traded:
|
(i)
|
on the TSX;
|
(ii)
|
if the Common Shares are not listed on the TSX, on any stock exchange upon which the Common Shares are listed as may be
selected for this purpose by the directors, acting reasonably and in good faith; or
|
(iii)
|
if the Common Shares are not listed on any stock exchange, on any over-the-counter market;
|
(r)
|
“Date of Issue” for a particular Warrant means the date on which the Warrant is
actually issued by or on behalf of the Company;
|
(s)
|
“Director” means a director of the Company for the time being, and, unless
otherwise specified herein, reference to “action by the Directors” means action by the Directors of the Company as a board, or whenever duly empowered, action by any committee of such board;
|
(t)
|
“Dividend Paid in the Ordinary Course” means a dividend paid on the Common Shares
in any fiscal year of the Company in cash, provided that the aggregate amount of such dividend for each Common Share does not in such fiscal year exceed 5% of the Exercise Price, and for such purpose the amount of any dividend paid in
shares shall be the aggregate stated capital of such shares, and the amount of any dividend paid in other than cash or shares shall be the fair market value of such dividend as determined by a resolution passed by the Board of Directors of
the Company, subject, if applicable, to the prior consent of any stock exchange or any other over-the-counter market on which the Common Shares are traded;
|
(u)
|
“Exercise Date” with respect to any Warrant means the date on which the Warrant
Certificate representing such Warrant is surrendered for exercise in accordance with the provisions of Article IV;
|
(v)
|
“Exercise Period” means the period commencing on the time of issue on the Date of
Issue and ending at the Time of Expiry;
|
(w)
|
“Exercise Price” means a price per Common Share of US$3.00 unless such price shall
have been adjusted in accordance with the provisions of Section 5.1, in which case it shall mean such adjusted price in effect at such time;
|
(x)
|
“Extraordinary Resolution” has the meaning attributed thereto in Section 9.11;
|
(y)
|
“Filing Jurisdiction” means any of British Columbia, Alberta and Ontario;
|
(z)
|
“IAI” means an institutional “accredited investor” meeting one or more of the
criteria in Rule 501(a)(1), (2), (3), (7), (8), (9), (12), or (13) of Regulation D under the U.S. Securities Act;
|
(aa)
|
“Internal Procedures” means in respect of the making of any one or more entries
to, changes in or deletions of any one or more entries in the register at any time (including without limitation, original issuance or registration of transfer of ownership) the minimum number of the Warrant Agent’s internal procedures
customary at such time for the entry, change or deletion made to be complete under the operating procedures followed at the time by the Warrant Agent, it being understood that neither preparation and issuance shall constitute part of such
procedures for any purpose of this definition;
|
(bb)
|
“Offering” has the meaning ascribed to such term in the Prospectus;
|
(cc)
|
“Offshore Transaction” means “offshore transaction” as that term is defined in
Regulation S;
|
(dd)
|
“Person” means an individual, a corporation, a partnership, a syndicate, a trustee
or any unincorporated organization and words importing persons are intended to have a similarly extended meaning;
|
(ee)
|
“Prospectus” means the final short form prospectus of the Company dated February
18, 2021;
|
(ff)
|
“Qualified Institutional Buyer” means a “qualified institutional buyer” within the
meaning of Rule 144A under the U.S. Securities Act that is also an IAI;
|
(gg)
|
“Regulation D” means Regulation D adopted by the SEC under the U.S. Securities
Act;
|
(hh)
|
“Regulation S”
means Regulation S adopted by the SEC under the U.S. Securities Act;
|
(ii)
|
“Rights Offering” has the meaning attributed thereto in subsection 5.1(b);
|
(jj)
|
“Rights Period” has the meaning attributed thereto in subsection 5.1(b);
|
(kk)
|
“SEC” means the United States Securities and Exchange Commission;
|
(ll)
|
“Securities” means the Common Shares and Warrants;
|
(mm)
|
“Securities Laws” means, collectively, the applicable securities laws of the
Filing Jurisdiction, the regulations, rules, rulings and orders made thereunder, the applicable published policy statements issued by the applicable securities commissions thereunder, and the securities legislation and published policies of
each Filing Jurisdiction;
|
(nn)
|
“Shareholder” means a holder of record of one or more Common Shares;
|
(oo)
|
“Special Distribution” has the meaning attributed thereto in subsection 5.1(c);
|
(pp)
|
“Subsidiary of the Company” means a corporation of which voting securities
carrying a majority of the votes attached to all voting securities are held, directly or indirectly other than by way of security only, by or for the benefit of the Company, the Company and one or more subsidiaries thereof, or one or more
subsidiaries of the Company; and, as used in this definition, voting securities means securities of a class or series or classes or series carrying a voting right to elect directors under all circumstances provided that, for the purposes
hereof, securities which only carry the right to vote conditionally on the happening of an event shall not be considered voting securities whether or not such event shall have happened nor shall any securities be deemed to cease to be
voting securities solely by reason of a right to vote accruing to securities of another class or series or classes or series by reason of the happening of such event;
|
(qq)
|
“this Warrant Indenture”, “this Indenture”,
“herein”, “hereby”, and similar expressions mean and refer to this Indenture and any indenture, deed or instrument supplemental or ancillary hereto; and the
expressions “Article”, “Section”, and “subsection” followed by a number mean and refer to the specified Article, Section or subsection of this Indenture;
|
(rr)
|
“Time of Expiry” means 5:00 p.m. (Toronto time) on February 24, 2023 (being the
date that is 24 months after the date of this Indenture);
|
(ss)
|
“TSX” means the Toronto Stock Exchange;
|
(tt)
|
“Uncertificated Warrant” means any Warrant which is not issued as part of a
Warrant Certificate;
|
(uu)
|
“Unit” has the meaning ascribed to such term in the Prospectus;
|
(vv)
|
“United States” means the United States of America as that term is defined in
Regulation S;
|
(ww)
|
“U.S. Exchange Act” means the United States Securities Exchange Act of 1934, as
amended;
|
(xx)
|
“U.S. Person” means a “U.S. person” as that term is defined in Regulation S;
|
(yy)
|
“U.S. Purchaser” means an original purchaser of Units, of which the Warrants
comprise a part, who purchased on a substituted purchaser basis and who was, at the time of purchase, either an IAI or a Qualified Institutional Buyer and (a) a U.S. Person, (b) any person purchasing such Units on behalf of, or for the
account or benefit of, any U.S. Person or any person in the United States, (c) any person who receives or received an offer to acquire such Units while in the United States, and (d) any person who was in the United States at the time such
person’s buy order was made or the subscription agreement pursuant to which such Units were acquired was executed or delivered;
|
(zz)
|
“U.S. Securities Act” means the United States Securities
Act of 1933, as amended;
|
(aaa)
|
“U.S. Warrantholder” means any Warrantholder that (a) is a U.S. Person, (b) is in
the United States, (c) received an offer to acquire Warrants while in the United States, (d) was in the United States at the time such Warrantholder’s buy order was made or such Warrantholder executed or delivered its purchase order for the
Warrants, or (e) acquired Warrants in the United States or for the account or benefit of any U.S. Person or Person in the United States;
|
(bbb)
|
“Warrant” means each common share purchase warrant of the Company issued or to be
issued hereunder entitling the holder thereof to purchase one Common Share for each Warrant upon payment of the Exercise Price; provided that in each case the number and/or class of shares or securities receivable on the exercise of the
Warrant may be subject to increase or decrease or change in accordance with the terms and provisions hereof;
|
(ccc)
|
“Warrant Agent” means Computershare Trust Company of Canada, or its successors
hereunder;
|
(ddd)
|
“Warrant Certificate” means a certificate representing one or more Warrants
substantially in the form set forth in Schedule “A” hereto or such other form as may be approved by the Company, the Agent and the Warrant Agent. To the extent that the Warrants are in the non-certificated issuer system, then this term
shall mean the appropriate evidence of such warrants pursuant to the non-certificated issuer system;
|
(eee)
|
“Warrantholders” or “holders” without
reference to Common Shares means the Persons whose names are entered for the time being on the register maintained pursuant to Section 3.2(1);
|
(fff)
|
“Warrantholders’ Request” means an instrument signed in one or more counterparts
by Warrantholders entitled to purchase, in the aggregate, not less than 10% of the aggregate number of Warrants then unexercised and outstanding, which requests the Warrant Agent to take some action or proceeding specified therein; and
|
(ggg)
|
“written order of the Company”, “written request of the Company”, “written consent
of the Company” and “certificate of the Company” and any other document required to be signed by the Company, means, respectively, a written order, request, consent, certificate or other document signed in the name of the Company by any
officer or director and may consist of one or more instruments so executed.
|
1.2
|
Number and Gender
|
1.3
|
Interpretation Not Affected by Headings, Etc.
|
1.4
|
Day Not a Business Day
|
1.5
|
Governing Law
|
1.6
|
Currency
|
1.7
|
Meaning of “Outstanding”
|
1.8
|
Severability
|
1.9
|
Statutory References
|
ISSUE OF WARRANTS
2.1
|
Issue of Warrants
|
2.2
|
Form and Terms of Warrants
|
(1)
|
Subject to subsection 2.2(2), each Warrant authorized to be issued hereunder shall entitle the holder thereof to purchase
upon due exercise and upon due execution and endorsement of the subscription form on the Warrant Certificate or other instrument of subscription in such form as the Warrant Agent and/or the Company may from time to time prescribe and upon
payment of the Exercise Price in effect on the Exercise Date, one Common Share at any time during the Exercise Period, in accordance with the provisions of this Indenture.
|
(2)
|
The number of Common Shares which may be purchased pursuant to the Warrants and the Exercise Price shall be adjusted in
the events and in the manner specified in Section 5.1.
|
(3)
|
The Warrants may be issued in both certificated and uncertificated form, except that all Warrants originally issued to a
U.S. Purchaser (excluding Qualified Institutional Buyers) will be issued in certificated form only. Warrant Certificates for the Warrants shall be substantially in the form attached as Schedule “A” hereto, with such additions, variations
and changes as may be required or permitted by the terms of this Indenture, and which may from time to time be agreed upon by the Warrant Agent and the Company, and shall bear such legends and such distinguishing letters and numbers as the
Company may, with the approval of the Warrant Agent, prescribe. The Warrant Certificates shall be dated as of the date hereof or on such other Closing Date upon which Warrants shall be issued.
|
(4)
|
Subject to subsection 2.2(5), Warrant Certificates shall be issuable in any denomination.
|
(5)
|
If a Warrantholder is entitled to a fraction of a Warrant the number of Warrants issued to that Warrantholder shall be
rounded down to the nearest whole Warrant.
|
(6)
|
The Warrant Certificates may be engraved, lithographed or printed (the expression “printed” including for purposes hereof
both original typewritten material as well as mimeographed, mechanically, photographically, photostatically or electronically reproduced, typewritten or other written material), or partly in one form and partly in another, as the Company,
with the approval of the Warrant Agent, may determine. No change in the form of the Warrant Certificate shall be required by reason of any adjustment made pursuant to Section 5.1 in the number and/or class of securities or type of
securities that may be acquired pursuant to the Warrants.
|
2.3
|
Issue in Substitution for Lost Warrant Certificates
|
(1)
|
In the event that any Warrant Certificates issued and certified under this Indenture shall be mutilated, lost, destroyed
or stolen, the Company, subject to applicable law, shall issue and thereupon the Warrant Agent shall certify and deliver, a new certificate of like tenor, and bearing the same legends, as the one mutilated, lost, destroyed or stolen in
exchange for and in place of and upon cancellation of such mutilated certificate, or in lieu of and in substitution for such lost, destroyed or stolen certificate, and the substituted certificate shall be in a form approved by the Warrant
Agent and shall be entitled to the benefits hereof and shall rank equally in accordance with its terms with all other Warrant Certificates issued or to be issued hereunder.
|
(2)
|
The applicant for the issue of a new certificate pursuant to this Section 2.3 shall bear the reasonable cost of the issue
thereof and in case of loss, destruction or theft shall, as a condition precedent to the issue thereof, furnish to the Company and to the Warrant Agent such evidence of ownership and of the loss, destruction or theft of the certificate so
lost, destroyed or stolen as shall be satisfactory to the Company and to the Warrant Agent in their sole discretion, acting reasonably, and such applicant shall also be required to furnish an indemnity and surety bond in amount and form
satisfactory to the Company and the Warrant Agent, each acting reasonably, to save each of them harmless, and shall pay the reasonable expenses, charges and any taxes applicable thereto to the Company and the Warrant Agent in connection
therewith.
|
2.4
|
Non-Certificated Deposit
|
(1)
|
Subject to the provisions hereof, at the Company’s option, Warrants, other than those issued pursuant to a U.S. Purchaser
(excluding Qualified Institutional Buyers) (which will be evidenced in certificated form only bearing the legends set forth in Section 2.9), will be issued and registered in the name of CDS or its nominee and:
|
(A)
|
may be directly deposited by the Warrant Agent to CDS; and
|
(B)
|
shall be identified by the CUSIP/ISIN 88830X363/CA88830X3638.
|
(2)
|
If the Company issues Warrants in a non-certificated format, Beneficial Owners of such Warrants registered and deposited
with CDS shall not receive Warrant Certificates in definitive form and shall not be considered owners or holders thereof under this Indenture or any supplemental agreement. Beneficial interests in Warrants registered and deposited with CDS
will be represented only through the non-certificated inventory system administered by CDS. Transfers of Warrants registered and deposited with CDS between CDS Participants shall occur in accordance with the rules and procedures of CDS.
Neither the Company nor the Warrant Agent shall have any responsibility or liability for any aspects of the records relating to or payments made by CDS or its nominee, on account of the beneficial interests in Warrants registered and
deposited with CDS. Nothing herein shall prevent the Beneficial Owners of Warrants registered and deposited with CDS from voting such Warrants using duly executed proxies.
|
(3)
|
All references herein to actions by, notices given or payments made to Warrantholders shall, where Warrants are held
through CDS, refer to actions taken by, or notices given or payments made to, CDS upon instruction from the CDS Participants in accordance with its rules and procedures. For the purposes of any provision hereof requiring or permitting
actions with the consent of or at the direction of Warrantholders evidencing a specified percentage of the aggregate Warrants outstanding, such direction or consent may be given by Beneficial Owners acting through CDS and the CDS
Participants owning Warrants evidencing the requisite percentage of the Warrants. The rights of a Beneficial Owner whose Warrants are held through CDS shall be exercised only through CDS and the CDS Participants and shall be limited to
those established by law and agreements between such Beneficial Owners and CDS and the CDS Participants upon instructions from the CDS Participants. Each of the Warrant Agent and the Company may deal with CDS for all purposes (including the
making of payments) as the authorized representative of the respective Warrants and such dealing with CDS shall constitute satisfaction or performance, as applicable, of their respective obligations hereunder.
|
(4)
|
For so long as Warrants are held through CDS, if any notice or other communication is required to be given to
Warrantholders, the Warrant Agent will give such notices and communications to CDS.
|
(5)
|
If CDS resigns or is removed from its responsibility as Depository and the Warrant Agent is unable or does not wish to
locate a qualified successor, CDS shall provide the Warrant Agent with instructions for registration of Warrants in the names and in the amounts specified by CDS and the Company shall issue and the Warrant Agent shall certify and deliver
the aggregate number of Warrants then outstanding in the form of definitive Warrant Certificates representing such Warrants.
|
(6)
|
Every Warrant Authenticated upon registration of transfer of an Uncertificated Warrant, or in exchange for or in lieu of
an Uncertificated Warrant or any portion thereof, whether pursuant to this Section 2.4 or otherwise, shall be Authenticated in the form of, and shall be, an Uncertificated Warrant, unless such Warrant is registered in the name of a person
other than the Depository for such Uncertificated Warrant or a nominee thereof.
|
(7)
|
The rights of Beneficial Owners who hold securities entitlements in respect of the Warrants through the non-certificated
inventory system administered by CDS shall be limited to those established by applicable law and agreements between the Depository and the CDS Participants and between such CDS Participants and the Beneficial Owners who hold securities
entitlements in respect of the Warrants through the non-certificated inventory system administered by CDS, and such rights must be exercised through a CDS Participant in accordance with the rules and procedures of the Depository.
|
(8)
|
Notwithstanding anything herein to the contrary, neither the Company nor the Warrant Agent nor any agent thereof shall
have any responsibility or liability for:
|
(A)
|
the electronic records maintained by the Depository relating to any ownership interests or any other interests in the
Warrants or the depository system maintained by the Depository, or payments made on account of any ownership interest or any other interest of any person in any Warrants represented by an electronic position in the non-certificated
inventory system administered by CDS (other than the Depository or its nominee);
|
(B)
|
for maintaining, supervising or reviewing any records of the Depository or any CDS Participant relating to any such
interest; or
|
(C)
|
any advice or representation made or given by the Depository or those contained herein that relate to the rules and
regulations of the Depository or any action to be taken by the Depository on its own direction or at the direction of any CDS Participant.
|
(9)
|
The Company may terminate the application of this Section 2.4 in its sole discretion in which case all Warrants shall be
evidenced by Warrant Certificates registered in the name of a person other than the Depository.
|
(10)
|
Notwithstanding the foregoing, upon request of the Beneficial Owner, through the Depository, the Warrant Agent shall issue
a Warrant Certificate in respect of the interest of such Beneficial Owner, in which case the Uncertificated Warrant representing such Warrants shall be reduced accordingly and such Warrants shall be duly registered as directed by the
Depository.
|
2.5
|
Warrantholder not a Shareholder
|
2.6
|
Warrants to Rank Pari Passu
|
2.7
|
Signing of Warrant Certificates
|
2.8
|
Certification by the Warrant Agent
|
(1)
|
No Warrant Certificate shall be issued or, if issued, shall be valid for any purpose or entitle the registered holder to
the benefit hereof or thereof until it has been certified by manual signature by or on behalf of the Warrant Agent, and such certification by the Warrant Agent upon any Warrant Certificate shall be conclusive evidence as against the Company
that the Warrant Certificate so certified has been duly issued hereunder and that the holder is entitled to the benefit hereof.
|
(2)
|
The certification of the Warrant Agent on Warrant Certificates issued hereunder shall not be construed as a representation
or warranty by the Warrant Agent as to the validity of this Indenture or the Warrant Certificates (except the due certification thereof) and the Warrant Agent shall in no respect be liable or answerable for the use made of the Warrant
Certificates or any of them or of the consideration therefor nor for any breach by the Company of its covenants herein, except as otherwise specified therein.
|
2.9
|
Legended Warrant Certificates
|
(1)
|
The Warrant Agent understands and acknowledges that the Warrants and Common Shares issuable upon exercise of the Warrants
have not been, and will not be, registered under the U.S. Securities Act or the securities laws of any state of the United States.
|
(2)
|
Each Warrant Certificate originally issued to a U.S. Purchaser, and all certificates representing Common Shares issued
upon exercise of such Warrants, as well as all certificates issued in exchange thereof or in substitution thereof, shall, until such time as the same is no longer required under applicable requirements of the U.S. Securities Act and
applicable state securities laws, bear a legend substantially to the following effect:
|
(3)
|
If a Warrant Certificate is tendered for transfer and bears the legend set forth in subsection 2.9(2) hereof, the Warrant
Agent or the registrar and transfer agent, as the case may be, shall not register such transfer unless the holder complies with the requirements of the said subsection 2.9(2) hereof.
|
2.10
|
Copy of Indenture
|
EXCHANGE AND OWNERSHIP OF WARRANTS; NOTICES
3.1
|
Exchange of Warrant Certificates
|
(1)
|
Warrant Certificates entitling Warrantholders to purchase any specified number of Common Shares may, upon compliance with
the reasonable requirements of the Warrant Agent, be exchanged for one or more Warrant Certificates in any other authorized denomination bearing the same legends representing in the aggregate an equal number of Warrants as the number of
Warrants represented by the Warrant Certificates being exchanged. The Company shall sign all Warrant Certificates necessary to carry out exchanges as aforesaid and such Warrant Certificates shall be certified by or on behalf of the Warrant
Agent.
|
(2)
|
Warrant Certificates may be exchanged only at the principal transfer office of the Warrant Agent in the City of Toronto,
Ontario or at any other place that is designated by the Company with the approval of the Warrant Agent. Any Warrant Certificates tendered for exchange shall be surrendered to the Warrant Agent or its agents and cancelled.
|
(3)
|
Except as otherwise herein provided, any Warrant Agent may charge the holder requesting an exchange a reasonable sum for
each new Warrant Certificate issued in exchange for Warrant Certificate(s); and payment of such charges and reimbursement of the Warrant Agent or the Company for any and all stamp taxes or governmental or other charges required to be paid
shall be made by such holder as a condition precedent to such exchange.
|
3.2
|
Registration of Warrants
|
(1)
|
The Company shall, at all times while any Warrants are outstanding, cause the Warrant Agent and its agents to maintain a
register in which will be entered in alphabetical order the names, latest known addresses of the Warrantholders and particulars of the Warrants held by them, and a register of transfers in which shall be entered the particulars of all
transfers of Warrants, such registers to be kept by and at the principal transfer office of the Warrant Agent in the City of Toronto.
|
(2)
|
At the office of the Warrant Agent during normal business hours, the holder of a Warrant may have such Warrant transferred
in accordance with such reasonable requirements as the Warrant Agent may prescribe. The costs of any such transfer registration shall be borne by the transferee or presenter.
|
(3)
|
The registers referred to in this Section 3.2 shall at all reasonable times be open for inspection by the Company and by
any Warrantholder. The Warrant Agent, when requested in writing so to do by the Company, shall furnish the Company with a list of names and addresses of the Warrantholders showing the number of Warrants held by each Warrantholder.
|
(4)
|
Once an Uncertificated Warrant has been Authenticated, the information set forth in the register with respect thereto at
the time of Authentication may be altered, modified, amended, supplemented or otherwise changed only to reflect exercise or proper instructions to the Warrant Agent from the Warrantholder as provided herein, except that the Warrant Agent
may act unilaterally to make purely administrative changes internal to the Warrant Agent and changes to correct errors. Each person who becomes a Warrantholder of an Uncertificated Warrant, by his, her or its acquisition thereof shall be
deemed to have irrevocably (i) consented to the foregoing authority of the Warrant Agent to make such minor error corrections and (ii) agreed to pay to the Warrant Agent, promptly upon written demand, the full amount of all loss and expense
(including without limitation reasonable legal fees of the Company and the Warrant Agent plus interest, at an appropriate then prevailing rate of interest to the Warrant Agent), sustained by the Company or the Warrant Agent as a proximate
result of such error if but only if and only to the extent that such present or former Warrantholder realized any benefit as a result of such error and could reasonably have prevented, forestalled or minimized such loss and expense by
prompt reporting of the error or avoidance of accepting benefits thereof whether or not such error is or should have been timely detected and corrected by the Warrant Agent; provided, that no person who is a bona fide purchaser shall have
any such obligation to the Company or to the Warrant Agent.
|
3.3
|
Transfer of Warrants
|
(1)
|
No transfer of a Warrant will be valid unless entered on the register of transfers referred to in subsection 3.2(1), upon
surrender to the Warrant Agent of the Warrant Certificate evidencing such Warrant, and a duly completed and executed Transfer Form as attached to the Warrant Certificate executed by the registered holder or his executors, administrators or
other legal representatives or his or their attorney duly appointed by an instrument in writing in form and execution satisfactory to the Warrant Agent, and, upon compliance with the conditions herein and such reasonable requirements as the
Warrant Agent may prescribe, including compliance with all applicable securities legislation, such transfer will be recorded on the register of transfers by the Warrant Agent. Notwithstanding the foregoing, if the Warrants are
Uncertificated Warrants, the provisions of Section 3.2(4) shall apply.
|
(2)
|
The transferee of any Warrant will, after surrender to the Warrant Agent of the Warrant Certificate evidencing such
Warrant as required by subsection 3.3(1) and upon compliance with all other conditions in respect thereof required by this Indenture or by applicable law, be entitled to be entered on the register of holders referred to in subsection 3.2(1)
as the owner of such Warrant free from all equities or rights of set-off or counterclaim between the Company and the transferor or any previous holder of such Warrant, except in respect of equities of which the Company is required to take
notice by statute or by order of a court of competent jurisdiction.
|
(3)
|
The Company will be entitled, and may direct the Warrant Agent, to refuse to recognize any transfer, or enter the name of
any transferee, of any Warrant on the registers referred to in subsection 3.2(1), if such transfer would constitute a violation of the securities laws of any applicable jurisdiction or the rules, regulations or policies of any regulatory
authority having jurisdiction. The Warrant Agent is entitled to assume compliance with all applicable securities legislation unless otherwise notified in writing by the Company. The Warrant Agent shall have no obligation to ensure or verify
compliance with any applicable laws or regulatory requirements on the issue, exercise or transfer of any Warrants or any Common Shares issuable upon the exercise thereof provided such issue, exercise or transfer is effected in accordance
with the terms of this Warrant Indenture.
|
(4)
|
If a Warrant Certificate tendered for transfer bears the legend set forth in subsection 2.9(2), the Warrant Agent shall
not register such transfer unless the transferor has provided the Warrant Agent with the Warrant Certificate and complies with the requirements of the said subsection 2.9(2).
|
(5)
|
If the Warrant Certificate tendered for transfer does not bear the legend set forth in subsection 2.9(2), the Warrant
Agent shall not register such transfer unless the transferor has provided the Warrant Agent with the Warrant Certificate and a completed and executed transfer form in the form included in the Warrant Certificate. Notwithstanding the
foregoing, the Warrant Agent shall not register such transfer if the Warrant Agent has reason to believe that the transferee is a person in the United States or a U.S. Person or is acquiring the Warrants evidenced thereby for the account or
benefit of a person in the United States or a U.S. Person.
|
3.4
|
Ownership of Certificates
|
(1)
|
Except in connection with the registration of Uncertificated Warrants, the Company and the Warrant Agent and their
respective agents may deem and treat the holder of any Warrant Certificate as the absolute holder and owner of the Warrants evidenced thereby for all purposes, and the Company and the Warrant Agent shall not be affected by any notice or
knowledge to the contrary and, without limiting the foregoing, shall not be bound by notice of any trust or be required to see to the execution thereof.
|
(2)
|
Subject to the provisions of this Indenture and applicable law, a Warrantholder shall be entitled to the rights evidenced
by such Warrant Certificate free from all equities or rights of set-off or counterclaim between the Company and the original or any intermediate holder thereof and all persons may act accordingly and the receipt by any such holder of the
Common Shares obtainable pursuant thereto shall be a good discharge to the Company and the Warrant Agent for the same and neither the Company nor the Warrant Agent shall be bound to inquire into the title of any such holder, except where
the Company or the Warrant Agent is required to take notice by statute or by order of a court of competent jurisdiction.
|
3.5
|
Evidence of Ownership
|
(1)
|
Upon receipt of a certificate of any bank, trust company or other depositary satisfactory to the Warrant Agent stating
that the Warrants specified therein have been deposited by a named person with such bank, trust company or other depositary and will remain so deposited until the expiry of the period specified therein, the Company and the Warrant Agent may
treat the person so named as the owner, and such certificate as sufficient evidence of the ownership by such person of such Warrants during such period, for the purpose of any requisition, direction, consent, instrument or other document to
be made, signed or given by the holder of the Warrants so deposited.
|
(2)
|
The Company and the Warrant Agent may accept as sufficient evidence of the fact and date of the signing of any
requisition, direction, consent, instrument or other document by any person, the signature, as witness, of any officer of any trust company, bank or depositary satisfactory to the Warrant Agent, the certificate of any notary public or other
officer authorized to take acknowledgements of deeds to be recorded at the place where such certificate is made, that the person signing acknowledged to him the execution thereof, or a statutory declaration of a witness of such execution.
|
3.6
|
Notices
|
EXERCISE OF WARRANTS
4.1
|
Method of Exercise of Warrants
|
(1)
|
Subject to Section 4.8, upon and subject to the provisions hereof, the registered holder of any Warrant may exercise the
rights thereby conferred on him to purchase all or any part of the Common Shares to which such Warrant entitles the holder, by surrendering the Warrant Certificate representing such Warrants to the Warrant Agent during the Exercise Period
at its principal transfer office in Toronto, Ontario (or at any other place or places that may be designated by the Company from time to time with the approval of the Warrant Agent), with a duly completed and executed subscription form of
the registered holder or his executors, administrators or other legal representative or his attorney duly appointed by an instrument in writing in the form and manner satisfactory to the Warrant Agent, substantially in the form attached to
the Warrant Certificate specifying the number of Common Shares subscribed for together with a certified cheque, money order or bank draft in lawful money of the United States payable to or to the order of the Company at par in Toronto,
Ontario in an amount equal to the Exercise Price applicable at the time of such surrender in respect of each Common Share subscribed for. A Warrant Certificate with the duly completed and executed subscription form together with the payment
of the Exercise Price shall be deemed to be surrendered only upon personal delivery thereof to or, if sent by mail or other means of transmission, upon actual receipt thereof by the Warrant Agent.
|
(2)
|
No Warrant represented by an Uncertificated Warrant may be exercised
unless, prior to such exercise, the Warrantholder of such Warrant shall have taken all other action necessary to exercise such Warrant in accordance with this Indenture and the Internal Procedures. Notwithstanding anything to the contrary
contained herein and subject to the Internal Procedures in force from time to time, a Beneficial Owner whose Warrants are represented by an Uncertificated Warrant who desires to exercise his or her Warrants must do so by causing a CDS
Participant to deliver to CDS, on behalf of the Beneficial Owner, a written notice of the Beneficial Owner’s intention to exercise Warrants in a manner acceptable to CDS. Forthwith upon receipt by CDS of such notice, as well as payment in
an amount equal to the product obtained by multiplying the Exercise Price by the number of Common Shares subscribed for, CDS shall deliver to the Warrant Agent a Confirmation. An electronic exercise of Uncertificated Warrants initiated by the CDS Participant shall constitute a
representation to both the Company and the Warrant Agent that the beneficial owner at the time of exercise of such Warrants (a) is not in the United States; (b) is not a U.S. Person and is not exercising such Warrants on behalf of a U.S.
Person or a person in the United States; (c) did not acquire the Warrants in the United States or on behalf of, or for the account or benefit of a U.S. Person or a person in the United States; (d) did not receive an offer to exercise the
Warrant in the United States; (e) did not execute or deliver the notice of the owner’s intention to exercise such Warrants in the United States; and (f) has, in all other respects, complied with the terms of Regulation S under the U.S.
Securities Act in connection with such exercise. If the CDS Participant is not able to make or deliver the foregoing representations by initiating the electronic exercise of the Uncertificated Warrants, then such Uncertificated Warrants
shall be withdrawn from the
book based registration system, by the CDS Participant and an individually registered Warrant Certificate shall be issued by the Warrant Agent to such Beneficial Owner or CDS Participant and the exercise procedures set forth in Section 4.1(1) shall be followed.
|
(3)
|
Payment by a Beneficial Owner representing the Exercise Price must be provided to the appropriate office of the CDS
Participant in a manner acceptable to it. A notice in form acceptable to the CDS Participant and payment from such Beneficial Owner should be provided to the CDS Participant sufficiently in advance so as to permit the CDS Participant to
deliver notice and payment to CDS and for CDS in turn to deliver notice and payment to the Warrant Agent prior to Expiry Time. CDS will initiate the exercise by way of the Confirmation and forward the Exercise Price electronically to the
Warrant Agent and the Warrant Agent will execute the exercise by issuing to CDS through the non-certified inventory system administered by CDS the Common Shares to which the exercising Beneficial Owner is entitled pursuant to the exercise.
Any expense associated with the exercise process will be for the account of the Beneficial Owner exercising the Warrants and/or the CDS Participant exercising the Warrants on its behalf.
|
(4)
|
Notwithstanding any provisions of this Warrant Indenture, a beneficial owner may exercise his Warrants or take any actions
under this Warrant Indenture in accordance with the rules and procedures of CDS.
|
(5)
|
Any subscription referred to in this Section 4.1 shall be signed by the Warrantholder, shall specify the person(s) in
whose name such Common Shares are to be issued, the address(es) of such person(s) and the number of Common Shares to be issued to each person, if more than one is so specified. If any of the Common Shares subscribed for are to be issued to
(a) person(s) other than the Warrantholder, the signatures set out in the subscription referred to in subsection 4.1(1) shall be guaranteed by a major Canadian chartered bank, or by a medallion signature guaranteed from a member of a
recognized Signature Medallion Guarantee Program and the Warrantholder shall pay to the Company all applicable transfer or similar taxes and the Company shall not be required to issue or deliver certificates evidencing Common Shares unless
or until such Warrantholder shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid or that no tax is due.
|
(6)
|
If, at the time of exercise of the Warrants, in accordance with the provisions of subsection 3.1(1), there are any trading
restrictions on the Common Shares pursuant to applicable securities legislation or stock exchange requirements, the Company shall, on the advice of counsel, endorse any certificates representing the Common Shares to such effect. The Warrant
Agent is entitled to assume compliance with all applicable securities legislation unless otherwise notified in writing by the Company.
|
4.2
|
Effect of Exercise of Warrants
|
(1)
|
Upon compliance by the Warrantholder with the provisions of Section 4.1, the Common Shares so subscribed for shall be
deemed to have been issued and the Person or Persons to whom such Common Shares are to be issued shall be deemed to have become the holder or holders of record of such Common Shares on the Exercise Date unless the share registers maintained
by the transfer agent for the Common Shares shall be closed on such date, in which case the Common Shares so subscribed for shall be deemed to have been issued, and such Person or Persons shall be deemed to have become the holder or holders
of record of such Common Shares on the date on which such registers were reopened and such Common Shares shall be issued at the Exercise Price in effect on the Exercise Date. To the extent the opening of the registers remains within the
control of the Warrant Agent, the Company and the Warrant Agent shall cause such registers to be open on Business Days.
|
(2)
|
Within three (3) Business Days following the due exercise of a Warrant pursuant to Section 4.1, the Warrant Agent shall
deliver to the Company a notice setting forth the particulars of all Warrants exercised, and the persons in whose names the Common Shares are to be issued (as applicable) and the addresses of such holders of the Common Shares.
|
(3)
|
Subject to Section 4.1(3), within five (5) Business Days of the due exercise of a Warrant pursuant to Section 4.1, or
within (10) Business Days of the due exercise of a Warrant if such exercise would result in a fraction of a Common Share, the Company shall cause its transfer agent to mail to the person in whose name the Common Shares so subscribed for are
to be issued, as specified in the subscription completed on the Warrant Certificate, at the address specified in such subscription, a certificate or certificates for the Common Shares to which the Warrantholder is entitled and, if
applicable, shall cause the Warrant Agent to mail a Warrant Certificate representing any Warrants not then exercised.
|
(4)
|
If at the time of exercise of the Warrants there remain trading restrictions on the Common Shares acquired upon such
exercise pursuant to applicable securities legislation or policy of any applicable regulatory body, the Company may, upon the advice of Counsel, endorse any Common Share certificates to such effect. Furthermore, the Company shall, or its
Counsel shall, notify the Warrant Agent in writing of any trading restrictions on the Common Shares acquired upon such exercise pursuant to applicable securities legislation or policy of any applicable regulatory body. Unless and until
advised in writing by the Company or its Counsel that a specific legend and trading restrictions apply to the Common Shares, the Warrant Agent shall be entitled to assume that no specific legend is required and that there are no trading
restrictions on the Common Shares.
|
4.3
|
Subscription for Less than Entitlement
|
4.4
|
No Fractional Common Shares
|
4.5
|
Expiration of Warrant Certificates
|
4.6
|
Cancellation of Surrendered Warrants
|
4.7
|
Accounting and Recording
|
(1)
|
The Warrant Agent shall promptly account to the Company with respect to Warrants exercised and forward to the Company (or
into an account or accounts of the Company with the bank or trust company designated by the Company for that purpose) all monies received on the purchase of Common Shares through the exercise of Warrants. All such monies, and any securities
or other instruments from time to time received by the Warrant Agent, shall be received in trust for, and shall be segregated and kept apart by the Warrant Agent in trust for, the Company.
|
(2)
|
The Warrant Agent shall record the particulars of the Warrant Certificates exercised which shall include the name or names
and addresses of the Persons who become holders of Common Shares on exercise and the Exercise Date and Warrant Certificate number.
|
4.8
|
Prohibition on Exercise by U.S. Persons; Exception
|
(1)
|
Warrants may not be exercised by or on behalf of, or for the account or benefit of, any U.S. Person or any person in the
United States unless an exemption is available from the registration requirements of the U.S. Securities Act and applicable state securities laws and the holder of the Warrants has furnished an opinion of counsel of recognized standing in
form and substance satisfactory to the Company to such effect; provided that a U.S. Purchaser that purchased the Warrants in the United States will not be required to deliver an opinion of counsel in connection with the exercise of
Warrants, provided it provides the certification required in subsection 4.8(2)(b) or 4.8(2)(c) below. The Company shall be entitled to rely upon the registered address of the Warrantholder set forth in such Warrantholder’s Form of U.S.
Subscription Agreement for IAIs or Form of Qualified Institutional Buyer Letter attached to the U.S. Placement Memorandum, as applicable, under the Offering for the purchase of Units in determining whether the address is in the United
States or the Warrantholder is a U.S. Warrantholder.
|
(2)
|
Any holder which exercises any Warrants shall provide/certify substantially as follows, to the Company either:
|
(a)
|
the holder: (a) at the time of exercise of the Warrants is not in the United States; (b) is not a U.S. Person and is not
exercising the Warrants on behalf of a U.S. Person; and (c) has in all other aspects complied with the terms of an Offshore Transaction;
|
(b)
|
the holder: (a) acquired the Warrants directly from the Company pursuant to an executed Form of U.S. Subscription
Agreement for IAIs attached to the U.S. Placement Memorandum under the Offering for the purchase of Units; (b) is exercising the Warrants solely for its own account or for the benefit of a U.S. Person or a person in the United States for
whose account such holder acquired the Warrants directly from the Company and for whose account such holder exercises sole investment discretion; and (c) was, and any beneficial purchaser for whose account such holder acquired the Warrants
and is exercising the Warrants was, an IAI both on the date the Warrants were purchased from the Company and on Exercise Date of the Warrants;
|
(c)
|
the holder: (a) acquired the Warrants directly from the Company pursuant to an executed Qualified Institutional Buyer
Letter for Qualified Institutional Buyers attached to the U.S. Placement Memorandum under the Offering for the purchase of Units; (b) is exercising the Warrants solely for its own account or for the benefit of a U.S. Person or a person in
the United States for whose account such holder acquired the Warrants directly from the Company and for whose account such holder exercises sole investment discretion; and (c) was, and any beneficial purchaser for whose account such holder
acquired the Warrants and is exercising the Warrants was, a Qualified Institutional Buyer both on the date the Warrants were purchased from the Company and on Exercise Date of the Warrants; or
|
(d)
|
a written opinion of counsel of recognized standing in form and substance satisfactory to the Company to the effect that
an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available for the issuance of the Common Shares issuable on exercise of the Warrants.
|
(3)
|
No certificates representing Common Shares will be registered or delivered to an address in the United States unless the
holder of the Warrant complies with the requirements of paragraphs (b), (c) or (d) of subsection 4.8(2).
|
(4)
|
If a Common Share certificate issued with respect to an exercise of Warrants is tendered for transfer and bears the legend
set forth in subsection 2.9(2) hereof, the Warrant Agent or the transfer agent, as the case may be, shall not register such transfer unless the holder complies with the requirements of the said subsection 2.9(2).
|
ADJUSTMENT OF SUBSCRIPTION RIGHTS AND EXERCISE PRICE
5.1
|
Adjustment of Exercise Price and Number of Common Shares Purchasable Upon Exercise
|
(a)
|
Common Share Reorganization. If during the Exercise Period the Company shall:
|
(i)
|
issue Common Shares or securities exchangeable for or convertible into Common Shares to holders of all or substantially
all of its then outstanding Common Shares by way of stock dividend or other distribution (other than as a Dividend Paid in the Ordinary Course or a distribution of Common Shares upon exercise of the Warrants or pursuant to the exercise of
directors, officers or employee stock options granted under stock option plans of the Company), or
|
(ii)
|
subdivide, redivide or change its outstanding Common Shares into a greater number of Common Shares, or
|
(iii)
|
consolidate, reduce or combine its outstanding Common Shares into a lesser number of Common Shares,
|
(b)
|
Rights Offering.
If and whenever during the Exercise Period, the Company shall fix a record date for the issue of rights, options or warrants to all or substantially all of the holders of Common Shares under which such holders are entitled, during a
period expiring not more than forty-five (45) days after the record date for such issue (“Rights Period”), to subscribe for or purchase Common Shares or
securities exchangeable for or convertible into Common Shares at a price per share to the holder (or having a conversion price or exchange price per Share) of less than 95% of the Current Market Price for the Common Shares on such record
date (any of such events being called a “Rights Offering”), then the Exercise Price shall be adjusted effective immediately after the end of the Rights
Period to a price determined by multiplying the Exercise Price in effect immediately prior to the end of the Rights Period by a fraction:
|
(i)
|
the numerator of which shall be the aggregate of:
|
(1)
|
the number of Common Shares outstanding as of the record date for the Rights Offering, and
|
(2)
|
a number determined by dividing either
|
(a) |
where the event giving rise to the application of this subsection 5.1(b) was the issue of rights, options or warrants to the holders of Common Shares under which such holders are entitled
to subscribe for or purchase additional Common Shares, the product of the number of Common Shares issued or subscribed for during the Rights Period and the price at which such Common Shares are offered,
|
(b) |
where the event giving rise to the application of this subsection 5.1(b) was the issue of rights, options or warrants to the holders of Common Shares under which such holders are entitled
to subscribe for or purchase securities exchangeable for or convertible into shares, the product of the exchange or conversion price per share of such securities offered and the number of Common Shares for or into which the securities so
offered pursuant to the Rights Offering have been exchanged or converted during the Rights Period,
|
(ii)
|
the denominator of which shall be the number of Common Shares outstanding after giving effect to the Rights Offering and
including the number of Common Shares actually issued or subscribed for during the Rights Period upon exercise of the rights, warrants or options under the Rights Offering or upon the exercise of the exchange or conversion rights contained
in such exchangeable or convertible securities under the Rights Offering.
|
(c)
|
Special Distribution. If and whenever during the Exercise Period, the Company shall issue or distribute to all or to substantially all the holders of
the Common Shares:
|
(i)
|
securities of the Company including shares, rights, options or warrants to acquire shares of any class or securities
exchangeable for or convertible into or exchangeable into any such shares or cash, property or assets and including evidences of its indebtedness, or
|
(ii)
|
any cash, property or other assets,
|
(d)
|
Capital Reorganization. If and whenever during the Exercise Period there shall be a reclassification of Common Shares at any time outstanding or a change or exchange of the Common Shares into other shares or into other securities (other than a Common
Share Reorganization), or a consolidation, amalgamation, arrangement or merger of the Company with or into any other corporation or other entity (other than a consolidation, amalgamation, arrangement or merger which does not result in any
reclassification of the outstanding Common Shares or a change or exchange of the Common Shares into other securities), or a transfer of the undertaking or assets of the Company as an entirety or substantially as an entirety to another
corporation or other entity (any of such events being herein called a “Capital Reorganization”), the holder, where he has not exercised the right of
subscription and purchase under this Warrant Certificate prior to the effective date or record date, as the case may be, of such Capital Reorganization, shall be entitled to receive, and shall accept upon the exercise of such right for
the same aggregate consideration, in lieu of the number of Common Shares to which such holder was theretofore entitled upon such exercise, the aggregate number of shares, other securities or other property which such holder would have
been entitled to receive as a result of such Capital Reorganization if, on the effective date thereof, he had been the registered holder of the number of Common Shares to which such holder was theretofore entitled to subscribe for and
purchase; provided however, that no such Capital Reorganization shall be carried into effect unless all necessary steps shall have been taken to so entitle the holder. If determined appropriate by the board of directors of the Company,
acting reasonably and in good faith, and subject to the prior written approval of the principal Canadian stock exchange or over‑the-counter market on which the Common Shares are then listed or quoted for trading, appropriate adjustments
shall be made as a result of any such Capital Reorganization in the application of the provisions of this Indenture with respect the rights and interest thereafter of the Warrantholder to the end that the provisions of this Indenture
shall thereafter correspondingly be made applicable as nearly as may reasonably be possible in relation to any shares or other securities or property thereafter deliverable upon the exercise of the Warrants.
|
(e)
|
If and whenever at any time after the date hereof and prior to the Time of Expiry, the Company takes any action affecting
its Common Shares to which the foregoing provisions of this Section 5.1, in the opinion of the board of directors of the Company, acting reasonably and in good faith, are not strictly applicable, or if strictly applicable would not fairly
adjust the rights of the Holder against dilution in accordance with the intent and purposes thereof, or would otherwise materially affect the rights of the holder hereunder, then the Company shall execute and deliver to the holder an
amendment hereto providing for an adjustment in the application of such provisions so as to adjust such rights as aforesaid in such a manner as the board of directors of the Company may determine to be equitable in the circumstances, acting
reasonably and in good faith. The failure of the taking of action by the board of directors of the Company to so provide for any adjustment on or prior to the effective date of any action or occurrence giving rise to such state of facts
will be conclusive evidence that the board of directors has determined that it is equitable to make no adjustment in the circumstances.
|
5.2
|
Rules Regarding Calculation of Adjustment of Exercise Price and Number of Common Shares Purchasable
Upon Exercise
|
(1)
|
The adjustments provided for in Section 5.1 are cumulative, and shall, in the case of adjustments to the Exercise Price be
computed to the nearest one-tenth of one cent and shall be made successively whenever an event referred to therein shall occur, subject to the following paragraphs of this Section 5.2.
|
(2)
|
No adjustment in the Exercise Price shall be required unless such adjustment would result in a change of at least 1% in
the prevailing Exercise Price and no adjustment shall be made in the number of Common Shares purchasable upon exercise of the Warrants unless it would result in a change of at least one one‑hundredth of a Common Share; provided, however,
that any adjustments which, except for the provisions of this Section 5.2(2) would otherwise have been required to be made, shall be carried forward and taken into account in any subsequent adjustment.
|
(3)
|
No adjustment in the Exercise Price or in the number of Common Shares purchasable upon exercise of Warrants shall be made
in respect of any event described in Section 5.1, other than the events referred to in subsection 5.1(a)(ii) and 5.1(a)(iii), if the holder is entitled to participate in such event on the same terms, mutatis
mutandis, as if it had exercised its Warrants prior to or on the effective date or record date of such event. The terms of the participation of the holder in such event shall be subject to any necessary approval of the principal
Canadian stock exchange or over-the-counter market on which the Common Shares are then listed or quoted for trading.
|
(4)
|
No adjustment in the Exercise Price shall be made pursuant to Section 5.1 in respect of the issue from time to time:
|
(a)
|
of Common Shares purchasable on exercise of the Warrants governed by this Warrant Indenture;
|
(b)
|
of a Dividend Paid in the Ordinary Course of Common Shares to holders of Common Shares who exercise an option or election
to receive substantially equivalent dividends in Common Shares in lieu of receiving a cash dividend pursuant to a dividend reinvestment plan or similar plan adopted by the Company in accordance with the requirements of the principal
Canadian stock exchange or over-the-counter market on which the Common Shares are then listed or quoted for trading and applicable securities laws;
|
(c)
|
of Common Shares pursuant to any stock option plan, stock purchase plan or benefit plan in force at the date hereof for
directors, officers, employees, advisers or consultants of the Company, as such option or plan is amended or superseded from time to time in accordance with the requirements of the principal Canadian stock exchange or over-the-counter
market on which the Common Shares are then listed or quoted for trading and applicable securities laws, and such other stock option plan, stock purchase plan or benefit plan as may be adopted by the Company in accordance with the
requirements of the principal Canadian stock exchange or over-the-counter market on which the Common Shares are then listed or quoted for trading and applicable securities laws;
|
(d)
|
of Common Shares as payment of interest on any outstanding notes;
|
(e)
|
of the issuance of securities in connection with strategic license agreements and other partnering arrangements of the
Company or any subsidiary thereof; or
|
(f)
|
of Common Shares as full or partial consideration in connection with a strategic merger, consolidation or purchase of
substantially all of the securities or assets of a corporation or other entity;
|
(5)
|
If a dispute shall at any time arise with respect to adjustments provided for in Section 5.1, such dispute shall, absent
manifest error, be conclusively determined by the Company’s Auditors, or if they are unable or unwilling to act, by such other firm of independent chartered accountants as may be selected by action by the Directors and any such
determination, absent manifest error, shall be binding upon the Company, the Warrant Agent and the Warrantholders. Notwithstanding the foregoing, such determination shall be subject to compliance with all regulatory requirements (including
the rules of any stock exchange or over‑the‑counter market on which the Common Shares are then listed or quoted for trading). Such auditors or accountants shall be provided access to all necessary records of the Company. In the event that
any such determination is made, the Company shall deliver a certificate to the Warrant Agent and a notice to the Warrantholders in the manner contemplated in Section 3.6 describing such determination.
|
(6)
|
If the Company shall set a record date to determine the holders of the Common Shares for the purpose of entitling them to
receive any dividend or distribution or any subscription or purchase rights and shall, thereafter and before the distribution to such shareholders of any such dividend, distribution or subscription or purchase rights, legally abandon its
plan to pay or deliver such dividend, distribution or subscription or purchase rights, then no adjustment in the Exercise Price or the number of Common Shares purchasable upon exercise of any Warrant shall be required by reason of the
setting of such record date.
|
(7)
|
In the absence of a resolution of the board of directors of the Company fixing a record date for any dividend or
distribution referred to in subsection 5.1(a)(i) or any Rights Offering or Special Distribution, the Company shall be deemed to have fixed as the record date therefor the date on which such dividend or distribution is effected.
|
(8)
|
As a condition precedent to the taking of any action which would require any adjustment in any of the subscription rights
pursuant to this Warrant Certificate, including the Exercise Price and the number or class of shares or other securities which are to be received upon the exercise thereof, the Company shall take any corporate action which may, in the
opinion of Counsel, be necessary in order that the Company have unissued and reserved in its authorized capital and may validly and legally issue as fully paid and non-assessable all the shares or other securities which the holder of such
Warrant Certificate is entitled to receive on the full exercise thereof in accordance with the provisions hereof.
|
(9)
|
In case the Company, after the date hereof, shall take any action affecting any Common Shares, other than action described
in Section 5.1, which in the opinion of the Directors acting reasonably and in good faith would materially affect the rights of Warrantholders, the Exercise Price and the number or class of shares or other securities which are to be
received upon the exercise thereof shall be adjusted in such manner, if any, and at such time, as the Directors, in their sole discretion acting in good faith, may determine to be equitable in the circumstances. Such adjustment to be
subject to TSX approval for so long as the Common Shares are listed for trading on the TSX. Failure of the taking of action by the Directors so as to provide for an adjustment in the Exercise Price and the number or class of shares or other
securities which are to be received upon the exercise thereof prior to the effective date of any action by the Company affecting the Common Shares shall be conclusive evidence that the directors have determined that it is equitable to make
no adjustment in the circumstances.
|
(10)
|
The Warrant Agent shall be entitled to act and rely on any adjustment calculations by the Company or the Company’s
Auditors.
|
(11)
|
On the happening of each and every such event set out in Section 5.1, the applicable provisions of the Warrant
Certificate, including the Exercise Price, shall, ipso facto, be deemed to be amended
accordingly and the Company shall take all necessary action so as to comply with such provisions as so amended.
|
5.3
|
Postponement of Subscription
|
(a) |
issuing to the Warrantholder of any Warrant exercised after such record date and before the occurrence of such event, the additional Common Shares issuable upon such exercise by reason of
the adjustment required by such event, and
|
(b) |
delivering to such Warrantholder any distributions declared with respect to such additional Common Shares after such Exercise Date and before such event;
|
5.4
|
Notice of Adjustment of Exercise Price and Number of Common Shares Purchasable Upon Exercise
|
(1)
|
At least ten (10) Business Days prior to the effective date or record date, as the case may be, of any event which
requires or might require adjustment in any of the subscription rights pursuant to this Warrant Certificate, including the Exercise Price and the number of Common Shares which are purchasable upon the exercise thereof, the Company shall be
required to (a) file with the Warrant Agent a certificate of the Company specifying the particulars of such event (including the record date or the effective date for such event) and, if determinable, the required adjustment and the
computation of such adjustment; and (b) give notice to the Warrantholders of the particulars of such event (including the record date or the effective date for such event) and, if determinable, the required adjustment. Notice to the
Warrantholders shall be given in the manner specified in Section 3.6.
|
(2)
|
In case any adjustment for which such notice has been given is not then determinable, the Company shall promptly after
such adjustment is determinable (a) file with the Warrant Agent a computation of such adjustment; and (b) give notice to the Warrantholders of the adjustment. Notice to the Warrantholders shall be given in the manner specified in
Section 3.6.
|
(3)
|
The Warrant Agent may, absent manifest error, for all purposes of the adjustment act and rely upon the certificate of the
Company or of the Company’s Auditors submitted to it pursuant to subsection 5.4(1) and on the accuracy of such certificate, calculations and formulas contained therein.
|
PURCHASES BY THE COMPANY
6.1
|
Purchases of Warrants for Cancellation
|
6.2
|
Optional Purchases by the Company
|
COVENANTS OF THE COMPANY
7.1
|
Covenants of the Company
|
(a) |
the Company will at all times maintain its existence and will carry on and conduct its business in a prudent manner in accordance with industry standards and good business practice, and
will keep or cause to be kept proper books of account in accordance with applicable law;
|
(b) |
the Company will reserve and keep available a sufficient number of Common Shares for issuance upon the exercise of Warrants issued by the Company;
|
(c) |
the Company will cause the Common Shares from time to time subscribed for pursuant to the Warrants issued by the Company hereunder, in the manner herein provided, to be duly issued in
accordance with the Warrants and the terms hereof;
|
(d) |
the Company will cause the certificates representing the Common Shares from time to time to be acquired, pursuant to the Warrants in the manner herein provided, to be duly issued and
delivered in accordance with the Warrants and the terms hereof;
|
(e) |
the Company shall make all requisite filings under the Securities Act (Ontario), the Securities Act (British Columbia) or the Securities Act (Alberta) and the regulations made thereunder
including those necessary to remain a reporting issuer not in default of any requirement of such acts and regulations;
|
(f) |
the Company shall use all reasonable efforts to maintain the listing of the Common Shares on the TSX (or such other recognized stock exchange as may be agreed upon by the Company and the
Agent) and to have the Common Shares issued pursuant to the exercise of the Warrants listed and posted for trading on the TSX (or such other recognized stock exchange as may be agreed upon by the Company and the Agent) as expeditiously as
possible;
|
(g) |
all Common Shares that shall be issued by the Company upon exercise of the rights provided for herein shall be issued as fully paid and non-assessable;
|
(h) |
the Company will perform and carry out all of the acts or things to be done by it as provided in this Indenture;
|
(i) |
the Company will promptly advise the Warrant Agent and the Warrantholders in writing of any default under the terms of this Indenture; and
|
(j) |
the Company confirms that as at the date of execution of this Indenture it does not have a class of securities registered pursuant to Section 12 of the U.S. Securities and Exchange Act of
1934, as amended or have a reporting obligation pursuant to Section 15(d) of the Act. The Company covenants that in the event that (i) any class of its securities shall become registered pursuant to Section 12 of the U.S. Securities and
Exchange Act or the Company shall incur a reporting obligation pursuant to Section 15(d) of the U.S. Securities and Exchange Act, or (ii) any such registration or reporting obligation shall be terminated by the Company in accordance with the
U.S. Securities and Exchange Act, the Company shall promptly deliver to the Warrant Agent an officers’ certificate notifying the Warrant Agent of such registration or termination and such other information as the Warrant Agent may require at
the time. The Company acknowledges that the Warrant Agent is relying upon the foregoing covenants in order to meet certain SEC obligations with respect to those clients who are filing with the SEC.
|
7.2
|
Warrant Agent’s Remuneration and Expenses
|
7.3
|
Performance of Covenants by Warrant Agent
|
7.4
|
Securities Filings
|
(1)
|
If, in the opinion of Counsel, any filing is required to be made with any governmental or other authority in Canada
(including the securities regulatory authorities or any exchange or quotation system upon which any securities of the Company are listed or quoted for trading), or any other step is required before any Common Shares issuable upon the
exercise of Warrants by a Warrantholder may properly and legally be issued in Canada, the Company covenants that it will take such action so required at its own expense.
|
(2)
|
The Company will give written notice of the issue of Common Shares pursuant to the exercise of Warrants, in such detail as
may be required, to each securities administrator in each jurisdiction in which there is legislation requiring the giving of such notice and to the TSX.
|
7.5
|
Certificates of No Default
|
ENFORCEMENT
8.1
|
Suits by Warrantholders
|
(1)
|
Warrantholders May Not Sue. Except to the extent that the rights of an individual Warrantholder or group of Warrantholders would be
prejudiced thereby, no Warrantholder has the right to institute any action or proceeding or to exercise any other remedy authorized hereunder for the purpose of enforcing any right on behalf of the Warrantholders as a whole or for the
execution of any trust or power hereunder or for the appointment of a liquidator or receiver or receiver and manager or for a receiving order under the Bankruptcy
and Insolvency Act (Canada) or to have the Company wound up or to file or prove a claim in any liquidation or bankruptcy proceedings, unless the Warrant Agent has received a Warrantholders’ Request directing it to take the
requested action and has been provided with sufficient funds or other security and/or such indemnity satisfactory to the Warrant Agent in respect of the costs, expenses and liabilities that may be incurred by it in so proceeding and the
Warrant Agent has failed to act within a reasonable time thereafter. If the Warrant Agent has so failed to act, but not otherwise, any Warrantholder acting on behalf of all Warrantholders will be entitled to take any of the proceedings
that the Warrant Agent might have taken hereunder. No Warrantholder has any right in any manner whatsoever to effect, disturb or prejudice the rights hereby created by its action or to enforce any right hereunder or under any Warrant,
except subject to the conditions and in the manner herein provided. Any money received as a result of a proceeding taken by any Warrantholder on behalf of all the Warrantholders hereunder must be forthwith paid to the Warrant Agent.
|
(2)
|
Warrant Agent not Required to Possess Warrants. All rights of action under this Indenture may be enforced by the Warrant Agent without the possession of any
of the Warrants or the production thereof on any trial or other proceedings relative thereto.
|
(3)
|
Warrant Agent May Institute Proceedings. The Warrant Agent shall be entitled and empowered, either in its own name or as Warrant Agent of an express
trust, or as attorney-in-fact for the Warrantholders, or in any one or more of such capacities, to file such proof of debt, amendment of proof of debt, claim, petition or other document as may be necessary or advisable in order to have
the claim of the Warrant Agent and the Warrantholders allowed in any insolvency, bankruptcy, liquidation or other judicial proceedings relative to the Company or its creditors or relative to or affecting its property. The Warrant Agent is
hereby irrevocably appointed (and the successive respective Warrantholders by taking and holding the same shall be conclusively deemed to have so appointed the Warrant Agent) the true and lawful attorney-in-fact of the respective
Warrantholders with authority to make and file in the respective names of the Warrantholders or on behalf of the Warrantholders as a class, subject to deduction from any such claims of the amounts of any claims filed by any of the
Warrantholders themselves if and to the extent permitted hereunder, any proof of debt, amendment of proof of debt, claim, petition or other document in any such proceedings and to receive payment of any sums becoming distributable on
account thereof, and to execute any such other papers and documents and to do and perform any and all such acts and things for and on behalf of the Warrantholders, as may be necessary or advisable in the opinion of the Warrant Agent
acting and relying on the advice of Counsel, in order to have the respective claims of the Warrant Agent and of the Warrantholders against the Company or its property allowed in any such proceeding, and to receive payment of or on account
of such claims; provided, however, that nothing contained in this Indenture shall be deemed to give the Warrant Agent, unless so authorized by Extraordinary Resolution, any right to accept or consent to any plan of reorganization or
otherwise by action of any character in such proceeding to waive or change in any way any right of any Warrantholder. The Warrant Agent shall also have the power, but not the obligation, at any time and from time to time to institute and
to maintain such suits and proceedings as it may be advised shall be necessary or advisable to preserve and protect its interests and the interests of the Warrantholders. Any such suit or proceeding instituted by the Warrant Agent may be
brought in the name of the Warrant Agent as Warrant Agent of an express trust, and any recovery of judgment shall be for the rateable benefit of the Warrantholders subject to the provisions of this Indenture. In any proceeding brought by
the Warrant Agent (and also any proceeding in which a declaratory judgment of a court may be sought as to the interpretation or construction of any provision of this Indenture, to which the Warrant Agent shall be a party), the Warrant
Agent shall be held to represent all the Warrantholders, and it shall not be necessary to make any Warrantholders parties to any such proceeding.
|
(4)
|
Subject to the provisions of this Section and otherwise in this Indenture, all or any of the rights conferred upon a
Warrantholder by the terms of a Warrant may be enforced by such Warrantholder by appropriate legal proceedings without prejudice to the right which is hereby conferred upon the Warrant Agent to proceed in its own name to enforce each and
all of the provisions herein contained for the benefit of all of the Warrantholders from time to time.
|
8.2
|
Limitation of Liability
|
MEETINGS OF WARRANTHOLDERS
9.1
|
Right to Convene Meetings
|
9.2
|
Notice
|
9.3
|
Chairman
|
9.4
|
Quorum
|
9.5
|
Power to Adjourn
|
9.6
|
Show of Hands
|
9.7
|
Poll and Voting
|
(1)
|
On every Extraordinary Resolution, and on any other question submitted to a meeting and after a vote by show of hands when
demanded by the chairman or by one or more of the Warrantholders acting in Person or by proxy, a poll shall be taken in such manner as the chairman shall direct. Questions other than those required to be determined by Extraordinary
Resolution shall be decided by a majority of votes cast on the poll.
|
(2)
|
On a show of hands, every Person who is present and entitled to vote, whether as a Warrantholder or as proxy for one or
more absent Warrantholders, or both, shall have one vote. On a poll, each Warrantholder present in person or represented by a proxy duly appointed by instrument in writing shall be entitled to one vote in respect of each Common Share which
he is entitled to purchase pursuant to the Warrant or Warrants then held or represented by him. A proxy need not be a Warrantholder. The chairman of any meeting shall be entitled, both on a show of hands and on a poll, to vote in respect of
the Warrants, if any, held or represented by him.
|
9.8
|
Regulations
|
(1)
|
Subject to the provisions of this Indenture, the Warrant Agent or the Company with the approval of the other party may
from time to time make and from time to time vary such regulations as it shall think fit:
|
(a)
|
for the deposit of voting certificates and instruments appointing proxies at such place and time as the Warrant Agent, the
Company or the Warrantholders convening the meeting, as the case may be, may in the notice convening the meeting direct;
|
(b)
|
for the deposit of voting certificates and instruments appointing proxies at some approved place or places other than the
place at which the meeting is to be held and enabling particulars of such instruments appointing proxies to be mailed, delivered or sent by facsimile transmission before the meeting to the Company or to the Warrant Agent at the place where
the same is to be held and for the voting of proxies so deposited as though the instruments themselves were produced at the meeting;
|
(c)
|
for the form of the voting certificates and instrument of proxy and the manner in which the form of proxy may be executed;
and
|
(d)
|
generally for the calling of meetings of Warrantholders and the conduct of business thereat including setting a record
date for Warrantholders entitled to receive notice of or to vote at such meeting.
|
(2)
|
Any regulations so made shall be binding and effective and the votes given in accordance therewith shall be valid and
shall be counted. Save as such regulations may provide, or as may be expressly provided for herein the only Persons who shall be recognized at any meeting as a Warrantholder, or be entitled to vote or be present at the meeting in respect
thereof (subject to Section 9.9) shall be Warrantholders or Persons holding voting certificates or proxies of Warrantholders.
|
9.9
|
Company, Warrant Agent and Warrantholders May be Represented
|
9.10
|
Powers Exercisable by Extraordinary Resolution
|
(a) |
to agree to any modification, abrogation, alteration, compromise or arrangement of the rights of Warrantholders or (with the consent of the Warrant Agent, such consent not to be
unreasonably withheld) the Warrant Agent in its capacity as Warrant Agent hereunder or on behalf of the Warrantholders against the Company whether such rights arise under this Indenture, the Warrant Certificate or otherwise, provided that,
without the written consent of the Company, following such action the rights of the Warrantholders or any individual Warrantholder shall not exceed the rights of the Warrantholders hereunder, or otherwise result in an increase of the
obligations and liabilities of the Company hereunder;
|
(b) |
to amend, alter or repeal any Extraordinary Resolution previously passed or sanctioned by the Warrantholders;
|
(c) |
to direct or to authorize the Warrant Agent, subject to its prior indemnification pursuant to subsection 11.1(2), to enforce any of the covenants on the part of the Company contained in
this Indenture or the Warrant Certificates or to enforce any of the rights of the Warrantholders in any manner specified in such Extraordinary Resolution or to refrain from enforcing any such covenant or right;
|
(d) |
to waive, and to direct the Warrant Agent to waive, any default on the part of the Company in complying with any provisions of this Indenture or the Warrant Certificates either
unconditionally or upon any conditions specified in such Extraordinary Resolution;
|
(e) |
to restrain any Warrantholder from taking or instituting any suit, action or proceeding against the Company for the enforcement of any of the covenants on the part of the Company
contained in this Indenture or the Warrant Certificates or to enforce any of the rights of the Warrantholders as set out in this Indenture;
|
(f) |
to assent to a compromise or arrangement with a creditor or creditors or a class or classes of creditors, whether secured or otherwise, and with holders of any shares or other securities
of the Company;
|
(g) |
to direct any Warrantholder who, as such, has brought any suit, action or proceeding to stay or to discontinue or otherwise to deal with the same upon payment of the costs, charges and
expenses reasonably and properly incurred by such Warrantholder in connection therewith; and
|
(h) |
to remove the Warrant Agent and appoint a successor warrant agent in the manner specified in Section 11.7 hereof.
|
9.11
|
Meaning of Extraordinary Resolution
|
(1)
|
The expression “Extraordinary Resolution” when used in this Indenture means, subject as hereinafter provided in this
Section 9.11 and in Section 9.14, a resolution (i) passed at a meeting of the holders of Warrants duly convened for that purpose and held in accordance with the provisions of this Article IX at which there are holders of Warrants present in
person or represented by proxy representing at least 25% of the aggregate number of all the then outstanding Warrants and passed by the affirmative vote of Warrantholders representing not less than 66 2/3% of the aggregate number of all the
then outstanding Warrants represented at the meeting and voted on the poll upon such resolution; or (ii) adopted by an instrument in writing signed by the holders of Warrants representing not less than 66 2/3% percent of the aggregate
number of all the then outstanding Warrants.
|
(2)
|
If, at any meeting called for the purpose of passing an Extraordinary Resolution, Warrantholders entitled to purchase at
least 25% of the aggregate number of all the then outstanding Warrants are not present in person or by proxy within 30 minutes after the time appointed for the meeting then the meeting, if convened by Warrantholders or on a Warrantholders’
Request, shall be dissolved; but in any other case it shall stand adjourned to such day, being not less than ten (10) Business Days later, and to such place and time as may be appointed by the chairman. Not less than three (3) days’ prior
notice shall be given of the time and place of such adjourned meeting in the manner provided for in Section 3.6. Such notice shall state that at the adjourned meeting the Warrantholders present in person or by proxy shall form a quorum but
it shall not be necessary to set forth the purposes for which the meeting was originally called or any other particulars. At the adjourned meeting the Warrantholders present in person or by proxy shall form a quorum and may transact the
business for which the meeting was originally convened and a resolution proposed at such adjourned meeting and passed by the requisite vote as provided in subsection 9.11(1) shall be an Extraordinary Resolution within the meaning of this
Indenture notwithstanding that Warrantholders representing at least 25% of all the then outstanding Warrants are not present in person or by proxy at such adjourned meeting.
|
(3)
|
Votes on an Extraordinary Resolution shall always be given on a poll and no demand for a poll on an Extraordinary
Resolution shall be necessary.
|
9.12
|
Powers Cumulative
|
9.13
|
Minutes
|
9.14
|
Instruments in Writing
|
9.15
|
Binding Effect of Resolutions
|
9.16
|
Holdings by Company Disregarded
|
SUPPLEMENTAL INDENTURES
10.1
|
Provision for Supplemental Indentures for Certain Purposes
|
(a) |
providing for the issue of additional Warrants hereunder and any consequential amendments hereto as may be required by the Warrant Agent, relying on advice of Counsel;
|
(b) |
setting forth any adjustments resulting from the application of the provisions of Section 5.1 or any modification affecting the rights of Warrantholders hereunder on exercise of the
Warrants, provided that any such adjustments or modifications shall be subject to compliance with all regulatory requirements (including the rules of any stock exchange or over-the-counter market on which the Common Shares are then listed or
quoted for trading);
|
(c) |
adding to or modifying the provisions hereof provided that such additions or modifications are not in the opinion of the Warrant Agent, relying on the advice of Counsel, prejudicial to
the rights or interests of the Warrantholders as a group;
|
(d) |
giving effect to any Extraordinary Resolution passed as provided in Article IX;
|
(e) |
making such provisions not inconsistent with this Indenture as may be necessary or desirable with respect to matters or questions arising hereunder, provided that such provisions are not,
in the opinion of the Warrant Agent, relying on the advice of Counsel, prejudicial to the rights or interests of the Warrantholders as a group;
|
(f) |
adding to or altering the provisions hereof in respect of the transfer of Warrants, making provision for the exchange of Warrant Certificates, and making any modification in the form of
the Warrant Certificates which does not affect the substance thereof;
|
(g) |
modifying any of the provisions of this Indenture or relieving the Company from any of the obligations, conditions or restrictions herein contained, provided that such modification or
relief shall be or become operative or effective only if, in the opinion of the Warrant Agent, relying on the advice of Counsel, such modification or relief in no way prejudices any of the rights or interests of the Warrantholders as a group
or of the Warrant Agent, and provided further that the Warrant Agent may in its sole discretion decline to enter into any such supplemental indenture which in its opinion may not afford adequate protection to the Warrant Agent when the same
shall become operative; and
|
(h) |
for any other purpose not inconsistent with the terms of this Indenture, including the correction or rectification of any ambiguities, defective or inconsistent provisions, errors,
mistakes or omissions herein, provided that in the opinion of the Warrant Agent, relying on the advice of Counsel, the rights or interests of the Warrant Agent and of the Warrantholders as a group are in no way prejudiced thereby.
|
10.2
|
Successor Companies
|
CONCERNING THE WARRANT AGENT
11.1
|
Indenture Legislation
|
(1)
|
If, and to the extent, any provision of this Indenture limits, qualifies or conflicts with a mandatory requirement of
applicable statutes of Canada and its provinces and the regulations under those statutes relating to warrant indentures (“Applicable Legislation”), such mandatory requirement shall prevail.
|
(2)
|
The Company and the Warrant Agent agree that each will at all times in relation to this Indenture and any action to be
taken hereunder observe and comply with and be entitled to the benefit of Applicable Legislation.
|
11.2
|
Rights and Duties of Warrant Agent
|
(1)
|
In the exercise of the rights and duties prescribed or conferred by the terms of this Indenture, the Warrant Agent shall
act honestly and in good faith with a view to the best interests of the Warrantholders and shall exercise that degree of care, diligence and skill that a reasonably prudent warrant agent would exercise in comparable circumstances. No
provision of this Indenture shall be construed to relieve the Warrant Agent from, or require any Person to indemnify the Warrant Agent against, liability for its own gross negligence, wilful misconduct or fraud. The duties and obligations
of the Warrant Agent shall be determined solely by the provisions hereof and, accordingly, the Warrant Agent shall only be responsible for the performance of such duties and obligations as it has undertaken herein. The Warrant Agent shall
retain the right not to act and shall not be held liable for refusing to act in circumstances that require the delivery to or receipt by the Warrant Agent of documentation unless it has received clear and reasonable documentation which
complies with the terms of this Indenture. Such documentation must not require the exercise of any discretion or independent judgement other than as contemplated by this Indenture. The Warrant Agent shall incur no liability with respect to
the delivery or non-delivery of any certificate or certificates whether delivered by hand, mail or any other means, provided that it has complied with the terms of this Indenture in respect of the discharging of its obligations in respect
of the delivery of such certificates. None of the provisions contained in this Indenture shall require the Warrant Agent to expend or to risk its own funds or otherwise to incur financial liability in the performance of any of its duties or
in the exercise of any of its rights or powers unless indemnified and funded as aforesaid.
|
(2)
|
The obligation of the Warrant Agent to commence or continue any act, action or proceeding for the purpose of enforcing any
rights of the Warrant Agent or the Warrantholders hereunder shall be conditional upon the Warrantholders furnishing, when required by notice in writing by the Warrant Agent, sufficient funds to commence or to continue such act, action or
proceeding and an indemnity reasonably satisfactory to the Warrant Agent to protect and to hold harmless the Warrant Agent, its officers, directors and employees against the costs, charges and expenses and liabilities to be incurred thereby
and any loss and damage it may suffer by reason thereof.
|
(3)
|
The Warrant Agent may, before commencing or at any time during the continuance of any such act, action or proceedings,
require the Warrantholders, at whose instance it is acting, to deposit with the Warrant Agent the Warrant Certificates held by them, for which the Warrant Agent shall issue receipts.
|
(4)
|
Every provision of this Indenture that by its terms relieves the Warrant Agent of liability or entitles it to rely upon
any evidence submitted to it is subject to the provisions of Section 11.12.
|
11.3
|
Evidence, Experts and Advisers
|
(1)
|
In addition to the reports, certificates, opinions and evidence required by this Indenture, the Company shall furnish to
the Warrant Agent such additional evidence of compliance with any provision hereof, and in such form as may be prescribed by Applicable Legislation or as the Warrant Agent may reasonably require by written notice to the Company.
|
(2)
|
The Warrant Agent shall be protected in acting and relying upon any written notice, request, waiver, consent, certificate,
receipt, statutory declaration or other paper or document furnished to it, not only as to its due execution and the validity and effectiveness of its provisions, but also as to the truth of and acceptability of any information therein
contained which it in good faith believes to be genuine and what it purports to be.
|
(3)
|
Proof of the execution of an instrument in writing, including a Warrantholders’ Request, by any Warrantholder may be made
by the certificate of a notary public, or other officer with similar powers, that the Person signing such instrument acknowledged to him the execution thereof, or by an affidavit of a witness to such execution or in any other manner which
the Warrant Agent may consider adequate.
|
(4)
|
The Warrant Agent may employ or retain such Counsel, accountants, appraisers or other experts or advisers as it may
reasonably require for the purpose of determining and discharging its duties hereunder and shall not be responsible for any misconduct or negligence on the part of such experts or advisors who have been appointed and supervised with due
care by the Warrant Agent. The fees of such Counsel and other experts shall be part of the Warrant Agent’s fees hereunder. The Warrant Agent shall be fully protected in acting or not acting and relying, in good faith, in accordance with any
opinion or instruction of such Counsel. Any remuneration so paid by the Warrant Agent shall be repaid to the Warrant Agent in accordance with Section 7.2.
|
11.4
|
Action by Warrant Agent to Protect Interest
|
11.5
|
Warrant Agent not Required to Give Security
|
11.6
|
Protection of Warrant Agent
|
(a) |
The Warrant Agent shall not be liable for or by reason of any statement of fact or recitals in this indenture or in the Warrant Certificates (except the representations contained in
Section 11.8 or in the certificate of the Warrant Agent on the Warrant Certificates) or be required to verify the same, but all such statements or recitals are and shall be deemed to be made by the Company;
|
(b) |
Nothing herein contained shall impose any obligation on the Warrant Agent to see to or to require evidence of the registration or filing (or renewal thereof) of this Indenture or any
instrument ancillary or supplemental hereto;
|
(c) |
The Warrant Agent shall not be bound to give notice to any Person or Persons of the execution hereof; and
|
(d) |
The Warrant Agent shall not incur any liability or responsibility whatever or be in any way responsible for the consequence of any breach on the part of the Company of any of the
covenants herein contained or of any acts of any Directors, officers, employees, agents or servants of the Company.
|
11.7
|
Replacement of Warrant Agent; Successor by Merger
|
(1)
|
The Warrant Agent may resign and be discharged from all further duties and liabilities hereunder, subject to this
subsection 11.7(1), by giving to the Company not less than 30 days prior notice in writing or such shorter prior notice as the Company may accept as sufficient. The Warrantholders by Extraordinary Resolution shall have power at any time to
remove the existing Warrant Agent and to appoint a new warrant agent. In the event of the Warrant Agent resigning or being removed as aforesaid or being dissolved, becoming bankrupt, going into liquidation or otherwise becoming incapable of
acting hereunder, the Company shall forthwith appoint a new warrant agent unless a new warrant agent has already been appointed by the Warrantholders; failing such appointment by the Company, the retiring Warrant Agent or any Warrantholder
may apply to a justice of the Ontario Superior Court of Justice (the “Court”), at the Company’s expense, on such notice as such justice may direct, for the appointment of a new warrant agent; but any
new warrant agent so appointed by the Company or by the Court shall be subject to removal as aforesaid by the Warrantholders. Any new warrant agent appointed under any provision of this Section 11.7 shall be a company authorized to carry on
the business of a transfer agent in the province of Ontario. On any such appointment the new warrant agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named herein as Warrant Agent
without any further assurance, conveyance, act or deed; but there shall be immediately executed, at the expense of the Company, all such conveyances or other instruments as may, in the opinion of Counsel, be necessary or advisable for the
purpose of assuring the same to the new warrant agent, provided that, any resignation or removal of the Warrant Agent and appointment of a successor warrant agent shall not become effective until the successor warrant agent shall have
executed an appropriate instrument accepting such appointment and, at the request of the Company, the predecessor Warrant Agent, upon payment of its outstanding remuneration and expenses, shall execute and deliver to the successor warrant
agent an appropriate instrument transferring to such successor warrant agent all rights and powers of the Warrant Agent hereunder.
|
(2)
|
Upon the appointment of a successor warrant agent, the Company shall promptly notify the Warrantholders thereof in the
manner provided for in Section 3.6.
|
(3)
|
This Indenture shall enure to the benefit of and be binding upon the parties hereto and their respective successors and
assigns. The Company agrees that the Warrant Agent may assign its rights and duties under this Indenture to one of its affiliates without the need for any further notice to, or approval from, the Company.
|
(4)
|
Any Warrants certified but not delivered by a predecessor Warrant Agent may be certified by the new or successor warrant
agent in the name of the predecessor or the new or successor warrant agent.
|
11.8
|
Conflict of Interest
|
(1)
|
The Warrant Agent represents to the Company that to the best of its knowledge at the time of execution and delivery hereof
no material conflict of interest exists in its role as a warrant agent hereunder and agrees that in the event of a material conflict of interest arising hereafter it shall immediately notify the Company of the material conflict of interest
with complete details of the conflict and such other information as the Company may reasonably request in connection therewith and, within ninety (90) days after ascertaining that it has such material conflict of interest, either eliminate
the same or resign its trusts hereunder to a successor warrant agent approved by the Company and meeting the requirements set forth in subsection 11.7(1). Notwithstanding the foregoing provisions of this subsection 11.8(1), if any such
material conflict of interest exists or hereinafter shall exist, the validity and enforceability of this Indenture and the Warrant Certificates shall not be affected in any manner whatsoever by reason thereof.
|
(2)
|
Subject to subsection 11.8(1), the Warrant Agent, in its personal or any other capacity, may buy, lend upon and deal in
securities of the Company and generally may contract and enter into financial transactions with the Company or any Subsidiary of the Company without being liable to account for any profit made thereby.
|
11.9
|
Warrant Agent Not to be Appointed Receiver
|
11.10
|
Payments by Warrant Agent
|
11.11
|
Deposit of Securities
|
11.12
|
Act, Error, Omission etc.
|
11.13
|
Indemnification
|
11.14
|
Notice
|
11.15
|
Reliance by the Warrant Agent
|
11.16
|
Privacy
|
11.17
|
Anti-Money Laundering
|
11.18
|
Force Majeure
|
ACCEPTANCE OF TRUSTS BY WARRANT AGENT
12.1
|
Appointment and Acceptance of Functions
|
GENERAL
13.1
|
Notice to the Company and the Warrant Agent
|
(1)
|
Unless herein otherwise expressly provided, any notice to be given hereunder to the Company and to the Warrant Agent shall
be in writing and may be given by mail, email or, if available for such party, by facsimile (with original copy to follow by mail) or by personal delivery and shall be addressed as follows:
|
(a) |
if to the Company, to
Titan Medical Inc.
155 University Avenue
Suite 750
Toronto, Ontario M5H 3B7
Attention: Monique L. Delorme
Email: [redacted]
|
with a copy to:
Borden Ladner Gervais LLP
Bay Adelaide Centre, East Tower 22 Adelaide Street West, Suite 3400 Toronto, Ontario M5H 3E3 Attention: Manoj Pundit
Facsimile: (416) 367-6749 Email: [redacted]
|
(b) |
if to the Warrant Agent, to
Computershare Trust Company of Canada
100 University Avenue 11th Floor Toronto, Ontario M5J 2Y1 Attention: General Manager, Corporate Trust Department
Facsimile: (416) 981-9777 Email: [redacted]
|
(2)
|
The Company or the Warrant Agent, as the case may be, may from time to time give notice in the manner provided in
subsection 13.1(1) of a change of address which, from the effective date of such notice and until changed by like notice, shall be the address of the Company or the Warrant Agent, as the case may be, for all purposes of this Indenture. A
copy of any notice of change of address of the Company given pursuant to this subsection 13.1(2) shall be sent to the principal transfer office of the Warrant Agent in the City of Toronto, Ontario and shall be available for inspection by
Warrantholders during normal business hours.
|
(3)
|
If, by reason of a strike, lockout or other work stoppage, actual or threatened, involving postal employees, any notice to
be given to the Warrant Agent or to the Company hereunder could reasonably be considered unlikely to reach its destination, such notice shall be valid and effective only if it is delivered to an officer of the party to which it is addressed
or if it is delivered to such party at the appropriate address provided in subsection 13.1(1) by facsimile or other means of prepaid, transmitted, recorded communication and any such notice delivered in accordance with the foregoing shall
be deemed to have been received on the date of delivery to such officer or if delivered by facsimile or other means of prepaid, transmitted, recorded communication, on the first Business Day following the date of the sending of such notice
by the Person giving such notice.
|
13.2
|
Time of the Essence
|
13.3
|
Counterparts and Formal Date
|
13.4
|
Discretion of Directors
|
13.5
|
Satisfaction and Discharge of Indenture
|
13.6
|
Provisions of Indenture and Warrant Certificates for the Sole Benefit of Parties and Warrantholders
|
13.7
|
Common Shares or Warrants Owned by the Company or its Subsidiaries Certificates to be Provided
|
TITAN MEDICAL INC.
|
||
By:
|
Signed “Monique Delorme”
|
|
Name:
|
Monique L. Delorme
|
|
Title:
|
Chief Financial Officer
|
COMPUTERSHARE TRUST COMPANY OF CANADA |
||
|
By: |
Signed “Robert Morrison”
|
|
Name: |
Robert Morrison
|
|
Title: |
Corporate Trust Officer
|
|
By: |
Signed “Neil Scott”
|
|
Name: |
Neil Scott
|
|
Title: |
Corporate Trust Officer
|
FORM OF WARRANT CERTIFICATE
155 University Avenue, Suite 750, Toronto, Ontario, M5H 3B7
CUSIP: 88830X363
|
|
ISIN: CA88830X3638
|
|
NO. ●
|
● WARRANTS
|
Each warrant entitling the holder to purchase one (1) common share of Titan Medical Inc.
|
TITAN MEDICAL INC.
|
||
By:
|
COMPUTERSHARE TRUST COMPANY OF CANADA
|
|||
Dated:
|
By:
|
TO: |
Computershare Trust Company of Canada
100 University Avenue
11th Floor, North Tower Toronto, ON M5J 2Y1
|
☐ | A. |
the undersigned holder: (a) at the time of exercise of the Warrants is not in the United States; (b) is not a “U.S. person” as defined in
Regulation S under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”); (c) is not exercising the Warrants for the account or benefit of any “U.S. person” or person in the
United States; (d) did not execute or deliver this Subscription Form within the United States; and (e) has in all other aspects complied with the terms of Regulation S under the U.S. Securities Act;
|
☐ | B. |
the undersigned holder: (a) purchased the Warrants as a part of the Units directly from the Company for its own account or for the account or benefit of an institutional “accredited
investor” meeting one or more of the criteria in Rule 501(a)(1), (2), (3), (7), (8), (9), (12) or (13) of Regulation D under the U.S. Securities Act (an “IAI”), pursuant to an executed Form of U.S.
Subscription Agreement for IAIs attached to the U.S. Placement Memorandum, for the purchase of Units of the Company; (b) is exercising the Warrants solely for its own account or the account or benefit of such other IAI for whose account such
holder exercises sole investment discretion; (c) was an IAI, both on the date the Units were purchased from the Company and on the date of the exercise of the Warrants; (d) if the Warrants are being exercised on behalf of another person, the
undersigned holder represents, warrants and certifies that such person was the beneficial purchaser for whose account the undersigned holder originally acquired Units, of which the Warrants form a part, and such beneficial purchaser was and
is an IAI, both on the date the Units were purchased from the Company and on the date of the exercise of the Warrants; and (e) the representations and warranties made by the holder or any beneficial purchaser, as the case may be, to the
Company in such holder’s Form of U.S. Subscription Agreement for IAIs remain true and correct on the Exercise Date; or
|
☐ | C. |
the undersigned holder: (a) purchased the Warrants as part of the Units directly from the Company for its own account or for the account or benefit of another “qualified institutional
buyer”, within the meaning of Rule 144A under the U.S. Securities Act that is also an IAI (a “Qualified Institutional Buyer”), pursuant to an executed Form of Qualified Institutional Buyer Letter for
Qualified Institutional Buyers attached to the U.S. Placement Memorandum, for the purchase of Units of the Company; (b) is exercising the Warrants solely for its own account or for the account or benefit of such other Qualified Institutional
Buyer for whose account such holder exercises sole investment discretion; (c) was a Qualified Institutional Buyer, both on the date the Units were purchased from the Company and on the date of the exercise of the Warrants; (d) if the Warrants
are being exercised on behalf of another person, the undersigned holder represents, warrants and certifies that such person was the beneficial purchaser for whose account the undersigned holder originally acquired Units of which the Warrants
form a part, and such beneficial purchase was and is a Qualified Institutional Buyer, both on the date the Units were purchased from the Company and on the date of the exercise of the Warrants; and (e) the representations and warranties made
by the holder or any beneficial purchaser, as the case may be, to the Company in such holder’s Form of Qualified Institutional Buyer Letter remain true and correct on the Exercise Date;
|
☐ | D. |
the undersigned holder has delivered to the Company an opinion of counsel (which will not be sufficient unless it is from counsel of recognized standing and in form and substance
satisfactory to the Company) to the effect that an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available for the issuance of the Common Shares issuable upon exercise of the
Warrants.
|
(1) |
Certificates will not be registered or delivered to an address in the United States unless either Box B, C or D above is checked.
|
(2) |
If Box B, C or D is checked, the certificate representing the Common Shares will bear a legend restricting transfer without registration under the U.S. Securities Act and applicable state
securities laws unless an exemption from registration is available. However, a Qualified Institutional Buyer who checks off Box C above, may enter their Common Shares issued upon exercise of their Warrants into CDS.
|
(3) |
If Box D above is checked, holders are encouraged to consult with the Company in advance to determine that the legal opinion tendered in connection with the exercise will be satisfactory
in form and substance to the Company. The undersigned hereby directs that the said Common Shares be issued as follows:
|
Name(s) in full
|
Address(es)
(including Postal Code)
|
Number(s) of
Common Shares
|
Signature Guaranteed
|
Name of Warrantholder
|
|
Name of Authorized Representative
|
Signature of Warrantholder or Authorized Representative
|
|
(Print Name of Subscriber)
|
||
Title or Capacity of Authorized Representative
|
Daytime Phone Number of Warrantholder or Authorized Representative
|
|
(Address of Subscriber in full)
|
☐ |
Please check this box if the securities are to be picked up at the office where the Warrant Certificate is surrendered, failing which the securities will be mailed to the address
indicated above.
|
(the “Transferee”),
|
(Residential Address of Transferee)
|
a)
|
the undersigned transferee (i) is not a “U.S. person” (as defined in Regulation S under the United States Securities Act of 1933, as amended,
the “U.S. Securities Act”), (ii) at the time of transfer is not within the “United States” (as defined in Regulation S under the U.S. Securities Act), and (iii) is not acquiring any of the Warrants
represented by this Warrant Certificate by or on behalf of any U.S. person or person within the United States, unless registered under the U.S. Securities Act and any applicable state securities laws or unless an exemption from such
registration is available; or
|
b)
|
if the proposed transfer is to, or for the account or benefit of, a U.S. person or to a person in the United States, the undersigned hereby
represents, warrants and certifies that the transfer of the Warrants is being completed pursuant to an exemption from the registration requirements of the U.S. Securities Act and any applicable state securities laws, in which case the
undersigned has furnished to the Company and the Warrant Agent an opinion of counsel of recognized standing in form and substance reasonably satisfactory to the Company to such effect.
|
☐ | (A) |
the transfer is being made only to the Company; or
|
☐
|
(B) |
the transfer is being made outside the United States in accordance with Rule 904 of Regulation S under the U.S. Securities Act, and in compliance with any applicable local securities
laws and regulations and the holder has provided herewith the Declaration for Removal of Legend attached as Schedule “B” to the Indenture, or
|
☐ | (C) |
the transfer is being made pursuant to the exemption from the registration requirements of the U.S. Securities Act provided by (i) Rule 144 or (ii) Rule 144A thereunder, and in either
case in accordance with applicable state securities laws; or.
|
☐ | (D) |
the transfer is being made within the United States or to, or for the account or benefit of, U.S. Persons, in accordance with a transaction that does not require registration under the
U.S. Securities Act or any applicable state securities laws and the undersigned has furnished to the Company and the Warrant Agent an opinion of counsel of recognized standing in form and substance reasonably satisfactory to the Company to
such effect.
|
Signature Guaranteed
|
(Signature of Holder, to be the same as appears on the face of this Warrant Certificate)
|
|
Print Name |
||
Address |
||
FORM OF DECLARATION FOR REMOVAL OF U.S. LEGEND
TO: |
Computershare Trust Company of Canada
as registrar and transfer agent for Common Shares and Warrants of
Titan Medical Inc. (the “Company”)
|
Dated: |
X |
||
Authorized signatory |
|||
Name of Seller (please print) |
|||
Name of authorized signatory (please print) |
|||
Title of authorized signatory(please print) |
Titan Medical Announces Closing of US $23M Bought Deal Offering Including Full Exercise of Over-Allotment Option
Not for Distribution to United States News Wire Services or for Dissemination in the United States
TORONTO--(BUSINESS WIRE)--February 24, 2021--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it closed its previously announced offering of 8,335,000 units of the Company (“Units”) sold on a “bought deal” basis for gross proceeds of US $20,004,000 (the “Offering”). Bloom Burton Securities Inc. acted as underwriter for the Offering and exercised its over-allotment option in full on the date hereof for an additional 1,250,250 Units and additional gross proceeds to the Company of US $3,000,600. The aggregate gross proceeds to the Company under the Offering were US $23,004,600.
Each Unit was issued at a price of US $2.40 per Unit and consisted of one common share in the capital of the Company (each a “Common Share”) and one half (1/2) of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant is exercisable to acquire one Common Share at an exercise price of US $3.00 per share until February 24, 2023.
The net proceeds of the Offering will be used to fund the development of the Company’s robotic surgical technologies and for general working capital.
The Units were offered by way of a short form prospectus in each of the provinces of British Columbia, Alberta, and Ontario pursuant to National Instrument 44-101 – Short Form Prospectus Distributions, and by way of private placement in the United States and to, or for the account or benefit of, “U.S. persons” (as defined in Regulation S under the United States Securities Act of 1933, as amended (the “1933 Act”)) pursuant to exemptions from the registration requirements under the 1933 Act, and pursuant to the applicable securities laws of any state of the United States.
The securities referred to in this news release have not been, nor will they be, registered under the 1933 Act and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This press release does not constitute an offer for sale of securities, nor a solicitation for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
About Titan Medical
Titan Medical Inc., a medical device company headquartered in Toronto, is focused on developing robotic assisted technologies for application in single access surgery. The Enos™ system, by Titan Medical, is being developed with dual 3D and 2D high-definition vision systems, multi-articulating instruments, and an ergonomic surgeon workstation. With the Enos system, Titan intends to initially pursue gynecologic surgical indications. Certain of Titan’s robotic assisted surgical technologies and related intellectual property have been licensed to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system.
Enos™ is a trademark of Titan Medical Inc.
For more information, visit www.titanmedicalinc.com.
Forward-Looking Statements of Titan Medical
This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws. Such statements reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements, including, without limitation, references to: the Company’s focus on the design and development of surgical technologies for robotic single access surgery, the use of proceeds from the Offering, that the Enos system is being developed with dual 3D and 2D high-definition vision systems, multi-articulating instruments and an ergonomic surgeon workstation and that Titan intends to initially pursue gynecologic surgical indications. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 (which may be viewed at www.sedar.com and at www.sec.gov) and in the “Risk Factors” section of the Company’s prospectus related to the Offering (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Contacts
Monique L. Delorme
Chief Financial Officer
+1-416-548-7522
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Middlefield Canadian Income PCC - Annual Financial Report
- Brüush Receives Additional Delisting Notification to Address at Hearing
- Progress on ABN AMRO share buyback programme 12 April – 18 April 2024
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!